Food Labeling: Nutrient Content Claims, General Principles; Health Claims, General Requirements and Other Specific Requirements for Individual Health Claims

Federal RegisterDec 21, 1995

Ask Donna

What actually matters in this document.

Text

[[Page 66206]]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 101

[Docket Nos. 94P-0390 and 95P-0241]

Food Labeling: Nutrient Content Claims, General Principles;

Health Claims, General Requirements and Other Specific Requirements for

Individual Health Claims

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is proposing to amend

its regulations on nutrient content claims and health claims to provide

additional flexibility in the use of these claims on food products.

These changes are intended to benefit public health by encouraging

manufacturers to use health claims and nutrient content claims that

will assist consumers in maintaining a healthy diet. The agency's

current regulations were issued in January of 1993 to implement the

Nutrition Labeling and Education Act of 1990. This document proposes

refinements to those regulations to allow additional synonyms for

nutrient content claims without specific preclearance by the agency,

permit health claims on certain foods that do not currently qualify

because they do not contain 10 percent of certain required nutrients,

permit the use of shortened versions of authorized health claims under

certain circumstances, eliminate some of the required elements for

health claims, and provide additional guidance for petitioners seeking

exemption from the disqualification of some foods from bearing a health

claim because they contain high levels of certain nutrients. FDA is

proposing these amendments in response to petitions submitted by the

National Food Processors Association (NFPA) and the American Bakers

Association (ABA).

DATES: Written comments by March 20, 1996. The agency is proposing that

any final rules that may issue based upon this proposal become

effective on the date of publication.

ADDRESSES: Written comments to the Dockets Management Branch (HFA-305),

Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville,

MD 20857, 301-443-1751.

FOR FURTHER INFORMATION CONTACT: F. Edward Scarbrough, Center for Food

Safety and Applied Nutrition (HFS-2), Food and Drug Administration, 200

C St. SW., Washington, DC 20204, 202-205-4561.

SUPPLEMENTARY INFORMATION:

I. Background

A. The Nutrition Labeling and Education Act of 1990

On November 8, 1990, the President signed into law the Nutrition

Labeling and Education Act of 1990 (the 1990 amendments) (Pub. L. 101-

535). This new law amended the Federal Food, Drug, and Cosmetic Act

(the act) in a number of important ways. Among the more notable aspects

of the 1990 amendments were that they confirmed FDA's authority to

regulate nutrient content and health claims on food labels and in food

labeling.

Section 403(r)(1)(A) of the act (21 U.S.C. 343(r)(1)(A)), which was

added by the 1990 amendments, provides that a product is misbranded if

it bears a claim that characterizes the level of a nutrient of the type

required to be included in nutrition labeling unless the claim uses

terms that are defined and designated in regulations adopted by FDA and

is made in accordance with all other regulatory requirements.

Similarly, section 403(r)(1)(B) of the act provides that a product is

misbranded if it bears a claim that characterizes the relationship of a

nutrient to a disease or health-related condition unless the claim is

made in accordance with the requirements of the act.

The 1990 amendments instruct the Secretary of Health and Human

Services (the Secretary) (and, by delegation, FDA) to issue regulations

defining nutrient content claims that characterize levels of nutrients

in food. The 1990 amendments also instruct the Secretary (and, by

delegation, FDA) to issue regulations authorizing health claims only if

he or she determines,

``based on the totality of publicly available scientific

evidence (including evidence from well-designed studies conducted in

a manner which is consistent with generally recognized scientific

procedures and principles), that there is significant scientific

agreement, among experts qualified by scientific training and

experience to evaluate such claims, that the claim is supported by

such evidence'' (section 403(r)(3)(B)(i) of the act).

Section 403(r)(3)(B)(ii) and (r)(3)(B)(iii) of the act describe the

information that must be included in any health claim authorized under

the act. The act provides that the claim shall be an accurate

representation of the significance of the substance in affecting the

disease or health-related condition, and that it shall enable the

public to comprehend the information and understand its significance in

the context of the total daily diet. Section 403(r)(4)(A)(i) of the act

also provides that any person may petition FDA to issue a regulation

authorizing a nutrient content or health claim.

In addition, the 1990 amendments directed FDA to consider 10

disease-nutrient relationships as possible subjects for health claims.

B. FDA's Implementation of the 1990 Amendments

In the Federal Register of January 6, 1993 (58 FR 2066-2941), FDA

adopted final rules that implemented the 1990 amendments to the act.

Among those final rules, Sec. 101.13 sets out general principles for

nutrient content claims and provides for their use on food labels.

Other regulations in subpart D of part 101 (21 CFR part 101) establish

specific requirements for nutrient content claims. These regulations

define specific terms such as ``free,'' ``low,'' ``good source,''

``high,'' ``reduced,'' ``less (or fewer),'' ``more,'' and ``light'' or

``lite,'' and establish values for these terms for various nutrients.

They also designate certain synonyms that can be used in place of these

defined terms (58 FR 2302). In addition, Sec. 101.69 establishes

procedures for petitioning the agency to authorize additional nutrient

content claims and provide for additional synonyms which, if

authorized, will be listed in the relevant regulations (Sec. 101.69)

(e.g., ``extra'' as a synonym for ``more'').

FDA also adopted final rules that implemented the health claims

provisions of the act (58 FR 2478). Section 101.14 establishes general

principles for health claims. This regulation prescribes the

circumstances in which a substance is eligible to be the subject of a

health claim (Sec. 101.14(b)), sets forth the standard in section

403(r)(3)(B)(i) of the act as the standard that the agency will apply

in deciding whether to authorize a claim about a substance-disease

relationship (101.14(c)), sets forth general rules on how authorized

claims are to be made in food labeling (Sec. 101.14(d)), and

establishes limitations on the circumstances in which claims can be

made (Sec. 101.14(e)). The agency also adopted Sec. 101.70, which

established a process for petitioning the agency to authorize health

claims about a substance-disease relationship (Sec. 101.70(a)) and sets

out the types of information that any such petition must include

(Sec. 101.70(f)).

At the same time, the agency announced its decisions regarding

health claims on the 10 disease-nutrient

[[Page 66207]]

relationships specified in the 1990 amendments. Of the 10, FDA

authorized health claims for calcium and osteoporosis (58 FR 2665);

dietary lipids and cancer (58 FR 2787); sodium and hypertension (58 FR

2820); dietary saturated fat and cholesterol and risk of coronary heart

disease (58 FR 2739); fiber-containing grain products, fruits, and

vegetables and cancer (58 FR 2537); fruits, vegetables, and grain

products that contain fiber, particularly soluble fiber, and risk of

coronary heart disease (58 FR 2552); and fruits and vegetables and

cancer (58 FR 2622). The regulations on general requirements for health

claims and on the claims specified above became effective May 8, 1993.

In the Federal Register of January 6, 1993 (58 FR 2066), FDA also

issued ``Food Labeling Regulations Implementing the Nutrition Labeling

and Education Act of 1990; Opportunity for Comments,'' (the

implementation final rule). The implementation final rule provided 30

days for interested persons to comment on technical issues arising in

any of the final rules implementing the 1990 amendments. In the Federal

Register of August 18, 1993 (58 FR 44020 to 44096), FDA published

technical amendments to the final rules in response to the comments it

received.

In the Federal Register of October 14, 1993 (58 FR 53254), FDA

proposed to authorize the use of a health claim about the relationship

between folate and the risk of neural tube defects on the labels or in

labeling of foods in conventional food form and dietary supplements.

This action was in response to provisions of the 1990 amendments and

the Dietary Supplement Act of 1992 (Pub. L. 102-571). In the Federal

Register of January 4, 1994 (59 FR 395), FDA announced that the

proposed regulation to authorize use of the health claim about the

association between folate and neural tube defects in food labeling was

considered a final regulation for dietary supplements of vitamins,

minerals, herbs, and other similar nutritional substances.

II. The Petition of the National Food Processors Association

The National Food Processors Association (NFPA) submitted a citizen

petition dated October 25, 1994, requesting initiation of rulemaking

for the adoption of amendments to the regulations governing nutrient

content and health claims. This petition was assigned FDA Docket No.

94P-0390.

For nutrient content claims, NFPA requested specific amendments to

Secs. 101.13 and 101.65 allowing use of synonyms and implied nutrient

content claims, without FDA preclearance, that are understood by

consumers to have the same meaning as a defined term, where such claims

are made in accordance with the requirements for the defined term, and

the defined term also appears in the product's labeling.

NFPA also requested several amendments to the health claim

regulations. Among other changes, NFPA requested that FDA permit the

use of an abbreviated or implied health claim with a referral statement

directing consumers to the complete claim elsewhere in labeling.

Currently, all required information must appear in one place without

other intervening material.

It also requested that health claims be permitted for foods with

levels of nutrients that FDA had determined increase the risk of other

diseases to the general population. Among the general requirements for

health claims, FDA established in Sec. 101.14(a)(5) levels of total

fat, saturated fat, cholesterol, and sodium in a food above which the

food is disqualified from making a health claim. These are identified

as ``disqualifying nutrient levels.'' In its petition, NFPA suggested

that FDA amend the regulation so that a food with a nutrient at a

disqualifying level would be prohibited from making a health claim only

if the nutrient is directly and adversely associated with the disease

to which the claim refers. Absent such an association, NFPA requested

that the presence of a nutrient above a threshold level not disqualify

a product from bearing a health claim but instead require disclosure of

that fact in labeling.

Finally, NFPA requested an amendment to Sec. 101.14(e)(6), which

prohibits a food in conventional food form from bearing a health claim

unless the food contains 10 percent or more of the Reference Daily

Intake or Daily Reference Value for vitamin A, vitamin C, iron,

calcium, protein, or fiber per reference amount customarily consumed

before any nutrient addition (the ``10 percent nutrient contribution

requirement''). NFPA requested that this prohibition be replaced by a

requirement that any food bearing a health claim that refers to an

added nutrient disclose the fact of that nutrient addition in labeling.

FDA issued a letter on May 11, 1995, granting most of the requests

to initiate rulemaking on the foregoing aspects of the petition

(hereinafter referred to as the May 11, 1995, letter). However, the

agency denied certain aspects of NFPA's petition, including NFPA's

request that FDA change the levels in Sec. 101.14(a)(5) from

disqualification levels to disclosure levels. Although the agency

recognized that it has the authority under section 403(r)(3)(A)(ii) of

the act to exempt any claim from the disqualifying nutrient levels if

it finds that the claim would ``assist consumers in maintaining healthy

dietary practices,'' the agency concluded that a generic change in its

regulations would not be consistent with the underlying goals of the

NLEA.

FDA acknowledged, however, that disclosure rather than

disqualification may be appropriate under certain circumstances. The

agency said it will seek more limited criteria to define the conditions

under which disclosure rather than disqualification could be permitted.

III. The Petition of the American Bakers Association

A citizen petition, dated July 27, 1995, was submitted to FDA by

the ABA (Docket No. 95P-0241/CP 1), requesting that FDA amend, among

other things, the regulatory provision in Sec. 101.14(e)(6) to permit

enriched cereal-grain products that conform to the standards of

identity in part 136, 137, or 139 (21 CFR part 136, 137, or 139), and

bread that conforms to the standard of identity for enriched bread in

Sec. 136.115, except that it contains whole wheat or other grain

products not permitted under that standard, to bear health claims. The

petition specifically requested that FDA amend Sec. 101.14(e)(6) to

read:

Except for dietary supplements, enriched grain products that

conform to a standard of identity in part 136, 137, or 139, and

bread that conforms to the standard of identity for enriched bread

in Sec. 136.115, except that it contains whole wheat or other grain

products not permitted under that standard, or where provided for in

other regulations in part 101, subpart E.

In the alternative, ABA suggested that the agency expand the list of

qualifying nutrients to include complex carbohydrates, niacin, or

thiamin or allow the 10 percent nutrient contribution requirement to

apply to all foods for which the summation of the Daily Value of the

applicable nutrients is 10 percent rather than requiring that the 10

percent be based on a single serving.

Because of the similarities in the NFPA and ABA petitions regarding

the 10 percent nutrient contribution and health claims, FDA is

responding to part of the ABA petition in this document, which

implements FDA's May 11, 1995, letter response to the NFPA petition.

Other issues raised in the ABA petition will be handled separately.

[[Page 66208]]

IV. The Proposals

As the petitioners have requested, the agency is reconsidering its

position on several of the issues raised in the NFPA and ABA petitions.

The agency is well within its legal authority to reconsider the issues

in the NFPA petition and propose changes to the current food labeling

regulations. ``An agency may always change its mind and alter its

policies.'' (See Conference of State Bank Examiners v. Office of Thrift

Supervision, 792 F. Supp. 837, 845 (D.D.C. 1992)). While the burden is

on the agency to justify the change from the status quo, that

justification need not consist of an affirmative demonstration that the

status quo is wrong. The agency need only supply ``a reasoned analysis

for the change.'' (See Center for Auto Safety v. Peck, 751 F.2d 1336,

1349 (D.C. Cir 1985) (citing Motor Vehicle Mfrs. Ass'n v. State Farm

Mutual, 463 U.S. 29, 41, 103 S.Ct. 2856, 2865-2866 (1983))). The agency

can justify its departure from past policy ``with reference to the

objectives underlying statutory scheme it purports to construe.'' (See

Simmons v. I.C.C., 829 F.2d 150, 156 (D.C. 1987)).

One of the primary purposes of the 1990 amendments was to educate

consumers about healthful dietary practices. The legislative history

states, ``Health claims supported by significant scientific agreement

can reinforce the Surgeon General's recommendations and help Americans

to maintain a balanced and healthful diet'' (Ref. 1).

If the current regulations hinder food companies who want to use

one of the FDA-authorized claims, as NFPA has alleged, this public

health objective will be frustrated. As the agency has stated, if valid

health claims are not being used, ``there is a cost imposed on society

in that some valuable information may not be conveyed to consumers''

(58 FR 2927 at 2940). Consumers cannot change their dietary practices

if they do not have the necessary information.

The agency is pleased that many food companies are using the health

claims on the labels of their products. While the agency has not done

an extensive survey, FDA notes that dozens of health claims have

appeared on products such as cereal, cookies, frozen dessert bars, egg

products, and frozen vegetables. Nonetheless, the agency is concerned

that health claims are not being used as extensively as they could be,

despite the fact that many foods qualify for such claims.

FDA also notes that food companies are submitting petitions seeking

approval of new claims. Since the final regulations have been

published, the agency has received two such petitions, one regarding

sugar alcohols and dental caries and one regarding oat products and

coronary heart disease. A proposed regulation to authorize a health

claim regarding sugar alcohols and dental caries was published in the

Federal Register on July 20, 1995 (60 FR 37502) (hereinafter referred

to as the sugar alcohols proposal). The agency expects to complete in

the very near future its evaluation of the petition regarding oat

products and coronary heart disease.

Accordingly, the agency is proposing changes to the regulations

regarding the use of synonyms for nutrient content claims, the 10

percent nutrient contribution requirement for health claims, the use of

abbreviated health claims, the specific requirements for individual

health claims, and disqualifying levels for health claims to facilitate

additional use of these claims.

A. Synonyms in Nutrient Content Claims

Section 403(r)(1)(A) and (r)(2) of the act state that claims that

either expressly or by implication characterize the level of a nutrient

(nutrient content claims) may be made in the label or labeling of a

food only if the characterization of the level made in the claim uses

terms that are defined in regulations of the agency. Based on these

provisions, the agency has defined expressed claims as any direct

statement about the level (or range) of a nutrient in the food

(Sec. 101.13(b)(1)). In addition, it has defined implied claims as

nutrient content claims that describe the food or an ingredient therein

in a manner that suggests that a nutrient is absent or present in a

certain amount (e.g., ``high in oat bran'') (Sec. 101.13(b)(2)(i)) or

that suggests that the food, because of its nutrient content, may be

useful in maintaining healthy dietary practices and is made in

association with an expressed claim or statement about a nutrient

(e.g., ``healthy, contains 3 grams of fat'') (Sec. 101.13(b)(2)(ii)).

The agency has specifically defined a number of expressed nutrient

content claims (``free,'' ``low,'' ``reduced,'' ``light,'' ``good

source,'' ``high,'' and ``more'') and provided for their synonyms,

e.g., ``no,'' ``little,'' ``contains,'' and ``rich in.'' The agency

also provided for certain implied nutrient content claims

(Sec. 101.65(c) and (d)). Finally, the agency has defined the implied

nutrient content claim ``healthy'' (Sec. 101.65(d)(2)).

The agency considered the use of additional synonyms for the

defined terms in the 1993 nutrient content claims final rule (58 FR

2302 at 2320). At that time the agency provided for a limited number of

specific synonyms and declined to provide for either long lists of

synonyms or conditions for use of unevaluated terms. The agency

concluded that permitting additional synonyms to be used in conjunction

with either a defined claim or a disclosure statement explaining the

synonym's intended meaning would not assist consumers in maintaining

healthy dietary practices (58 FR 2302 at 2320). The agency stated that

there is no provision in the act that allows for the use of undefined

synonyms in the absence of action by the agency. Because of time

constraints, in developing the final regulations FDA was unable to

fully study the suggested schemes for use of terms without preclearance

to determine whether a scheme could be devised that would constitute

approval by the agency without preclearance of each term.

The agency also considered but rejected (58 FR 2302 at 2373) the

suggestion that implied claims that are defined on the label be

permitted. The agency did provide for certain implied claims on

products that meet the definition for certain expressed claims and gave

specific examples of some of these claims in the preamble (58 FR 2302

at 2374) and in the regulations (Sec. 101.65(c)(3)) (e.g., ``high in

oat bran'' for foods that are a good source of fiber; ``no oil'' for

fat free foods).

In the October 25, 1994, petition, as stated above, NFPA requested

that the agency reconsider allowing synonyms and implied nutrient

content claims to be used without FDA preclearance under certain

circumstances. NFPA maintained that FDA's strict interpretation and

application of the 1990 amendments totally frustrated the achievement

of the various statutory goals of improving consumer education about

diet and health and thereby reducing the incidence of diet-related

diseases.

NFPA argued that, because the regulations sharply limit the

terminology that can be used to make nutrient content claims for food

products and require ``premarket clearance'' of terminology that FDA

has not specifically authorized by regulation, the regulations ban a

host of truthful and nonmisleading labeling statements. The petitioner

requested that FDA propose amendments that would permit nonmisleading

terms or statements that are reasonably understood by consumers to be

synonyms of a term defined in subpart D of part 101 to be used in

product labeling when the defined term also is used in the labeling.

Requesting similar amendments for implied claims, NFPA

[[Page 66209]]

stated that such amendments would ensure that claims characterizing the

level of a nutrient in a food are truthful and nonmisleading but would

give manufacturers greater freedom to construct such labeling messages

creatively.

In its May 11, 1995, response, FDA recognized that there may be

some merit to the argument that more latitude in the use of truthful,

nonmisleading nutrient content claims may assist consumers in

maintaining healthy dietary practices because greater flexibility would

provide the food industry with an increased incentive to develop more

healthful products. Permitting synonyms for defined terms to be used on

product labels without specific authorization for the particular

synonyms has the potential to provide the industry with a greater

variety of ways to convey nutrient information to the consumer because

the nutrient content claims on the label would not be restricted to a

finite list of terms that can only be expanded by filing an appropriate

petition. This approach could facilitate the industry's efforts to

arrive at terms that not only appropriately describe the nutrient level

in a food but also effectively catch the attention of the consumer.

In its May 11, 1995, letter, the agency noted that while a plethora

of uncontrolled terms would confuse consumers by diminishing the

usefulness of clearly defined and limited terms, NFPA's ``anchoring''

concept, if properly implemented, could offer the possibility of

increasing the available terms without confusing consumers. The agency

stated that it was granting NFPA's petition to initiate rulemaking on

the use of additional synonyms anchored to specifically authorized

terms.

Consequently, the agency is proposing to add new paragraph (r) to

Sec. 101.13, which provides that synonyms may be used in labeling in

accordance with one of two provisions. First, proposed

Sec. 101.13(r)(1) reflects the fact that a term may be used as a

synonym when the agency has specifically listed it as a synonym for a

defined term in one of the regulations listing authorized nutrient

content claims in subpart D of part 101 (``listed synonym''). FDA

included a number of synonyms in the regulation that it adopted as part

of the 1993 nutrient content claims final rule. It has also adopted

synonyms as a result of a petition filed in accordance with

Sec. 101.69(n). Additional synonyms may be added to FDA's regulations

following this procedure. Second, FDA is proposing in Sec. 101.13(r)(2)

to authorize the use of synonyms that are not specifically listed by

name in the regulations in subpart D of part 101, part 105, or part 107

(21 CFR part 105 or part 107) (``unlisted synonyms'') but are used in

labeling in accordance with the labeling requirements set out in this

provision.

Specifically, in Sec. 101.13(r)(2), the agency is proposing a

number of requirements to ensure that the use of unlisted synonyms will

not confuse or mislead consumers. In particular, FDA is proposing in

Sec. 101.13(r)(2)(i) to require that an unlisted term be reasonably

understood by consumers to be a synonym of a term defined in subpart D

of part 101, part 105, or part 107. Such an understanding is necessary

because the agency has, for example, defined the terms ``high'' and

``good source'' to represent two different levels of a nutrient.

Consumers can reasonably be expected to understand that ``without

any [nutrient]'' is the same as ``free of [nutrient],'' and that ``not

much'' of a nutrient is, in common usage, synonymous with ``low'' for

that nutrient since ``not much'' implies that some but not a lot of the

nutrient is present. Other ``synonyms'' however, may not be so clear.

It is important, therefore, that the use of unlisted synonyms that FDA

is proposing to authorize under Sec. 101.13(r)(2) be clear and

unambiguous to consumers regarding the levels to which they apply.

Without such clarity, consumers may be confused as to the nutrient

content of the food bearing the claim. Thus, regardless of the

prominent use of a listed term or other explanatory information

discussed below, terms that are not clearly understood by consumers to

be synonymous with specific listed terms may still be misleading and

misbrand the food under both section 403(a) and section 403(r)(1)(A) of

the act.

Further, the agency is concerned that different manufacturers might

use the same term but anchor it to different nutrient content claims.

For example ``plenty of fiber'' might be anchored to ``good source'' on

one product label and ``high'' on another. In this event, the agency

reserves the right to call for petitions to define the term by

regulation or to define the term on its own initiative.

The agency agrees with NFPA that, in addition to considering the

words of the individual claim, it is important to consider the meaning

of the unlisted synonym in the context of the entire product label. It

is possible, for instance, that other statements such as other nutrient

content claims on the label or in labeling could establish a context in

which the unlisted synonym would be misleading. Section 403(a) of the

act states that a food is misbranded if it bears any labeling statement

that is false or misleading in any particular. Therefore, proposed

Sec. 101.13(r)(2)(i) requires that the unlisted synonym not be

misleading in the context of the entire label.

The agency seeks comments as to whether further requirements should

be imposed to ensure that an unlisted term is truly synonymous with a

listed term. For example, FDA seeks comments as to whether it should

require companies to have data in their files demonstrating that

consumers understand the unlisted term to be synonymous with the listed

term in question as a condition for the use of the unlisted terms. In

addition, the agency seeks comments on why, if it includes such a

requirement, it should not also require that such data be available for

review by regulatory officials.

As stated above, for any term used as a synonym authorized under

proposed Sec. 101.13(r)(2) not to be misleading, the defined term for

which it purports to be a synonym would have to be clear to the

consumer. Proposed Sec. 101.13(r)(2)(ii)(A) will require that the

listed term appear prominently and conspicuously on the label.

Proposed Sec. 101.13(r)(2)(ii)(A)(1) requires the listed term

appear immediately adjacent to (with no intervening material) the most

prominent (as defined in Sec. 101.13(j)(2)(iii)) use of the unlisted

synonym. The agency tentatively concludes that having a listed term

immediately adjacent to the most prominent use of each such unlisted

synonym will help to ensure that consumers understand the claim that is

being made and thus to ascertain the level of the nutrient that the

food purports to contain.

The agency tentatively concludes that it is not sufficient for the

listed term to appear anywhere on the label, as suggested in the NFPA

petition. Such a scheme would not guarantee that the unlisted synonym

is read in conjunction with a listed term and would hinder the consumer

from ascertaining the level of the nutrient that the food purports to

have. For example, with such a provision, the unlisted synonym

authorized under Sec. 101.13(r)(2) could be very large and prominent,

and the listed term could be a part of the fine print (i.e., in small

print that is in sentence or paragraph form elsewhere on the label).

Although such defining information may be read by consumers at some

point, it would be unlikely to be fully read and comprehended at the

same

[[Page 66210]]

time as the unlisted term and thus would not make clear to the consumer

that the two statements are synonymous.

The agency's proposal is consistent with section 403(f) of the act

which deems a food to be misbranded if any word, statement, or other

information required by the act to appear on the label or labeling is

not prominently placed with such conspicuousness (as compared with

other words, statements, designs, or devices, in the labeling) and in

such terms as to render it likely to be read and understood by the

ordinary individual under customary conditions of purchase and use.

Section 403(f) of the act necessitates placement of the listed term on

the label so that it is likely to be read and understood, and thereby

to eliminate any ambiguity as to the meaning of the unlisted synonym.

Allowing the listed term to be anywhere on the label that the

manufacturer chooses would not ensure that this requirement is met.

There are a number of precedents for requiring clarifying

information in labeling to be adjacent to the text that it clarifies.

For example, Sec. 101.3(e) requires that the word ``imitation'' precede

the name of the food imitated; the term ``artificial'' is required by

Sec. 101.22(i)(1)(i), (i)(1)(ii), and (i)(3) to be adjacent to the name

of the flavor; and Sec. 102.5(b)(2) (21 CFR 102.5(b)(2)) requires that

if the percentage of a characterizing ingredient is required to be

included in the common or usual name of the food, it must be adjacent

to the name of the food. Further, several aspects of the nutrient

content claims regulations require that clarifying statements such as

the referral statement, ``See [side] panel for nutrition information''

(Sec. 101.13(g)); the disclosure statement, ``See [side] panel for

information about [sodium] and other nutrients'' (Sec. 101.13(h)); the

percentage reduction and identity of the reference food for a relative

claim (Sec. 101.14(j)(2)(ii)); and other clarifying information about

the food in relation to the claim, e.g., Sec. 101.13(i)(2) and (p)(2),

be immediately adjacent to the claim to which the statement pertains.

As with accompanying information for relative claims (i.e., percent

reduction in the nutrient and identity of the reference food

(Sec. 101.13(j)(2)(i) through (j)(2)(iii)), the agency considers the

presence of a listed term to be necessary to ensure that the claim is

understood by, and is not misleading to, consumers. However, as with

accompanying information, it recognizes that to require that this

information be included each time an unlisted synonym is used may

overburden the label. Consequently, as with relative claims, the agency

is proposing to require only that the defined term or listed synonym be

placed immediately adjacent to the most prominent declaration of each

unlisted synonym. Because of the similar purposes of the two

requirements, the agency believes that the provisions in

Sec. 101.1(j)(2)(iii) for determining the order of prominence of

relative claims are also appropriate for determining the order of

prominence of presentations of an unlisted synonym. The order of

prominence for relative claims is: (1) A claim on the principal display

panel adjacent to the statement of identity, (2) a claim elsewhere on

the principal display panel, (3) a claim on the information panel, or

(4) a claim elsewhere on the label or labeling.

The agency is proposing in Sec. 101.13(r)(2)(ii)(A)(2) that the

listed term be at least half as prominent as the unlisted synonym. If

it adopts these changes, FDA will evaluate prominence using type size,

style, and color. In the past, FDA has required certain clarifying

information to be in type at least half the size of that of the

statement it is clarifying. For example, when the term ``light'' is

used to describe a physical or organoleptic property of a food (e.g.,

``light in color''), the clarifying information ``in color'' is

required to be at least half the type size as the word ``light''

(Sec. 101.56(e)(2)). Similarly, when the term ``light'' is used on a

meal type product to describe a nutrient reduction, a clarifying

statement as to whether the food is ``low in calories'' or ``low in

fat'' is required and must be at least half the size of the term

``light'' (Sec. 101.56(d)(1)(ii)). Further, Sec. 102.5 requires that

the percentage declaration of a characterizing ingredient or component

be no less than half the height of the largest type appearing in the

common or usual name when it has a material bearing on the nature of

the product. Further, this information must appear in bold-faced type.

As a final example, Sec. 101.13(f) requires that any nutrient content

claim not be more than two times larger than, and not unduly prominent

in type style compared to, the statement of identity. All of these

provisions are examples of requirements where clarifying information

must be at least half as large or prominent as the statement that it is

clarifying.

FDA is proposing section 101.13(r)(2)(ii)(A)(1) and

(r)(2)(ii)(A)(2) to ensure that the combination of unlisted and listed

terms that appear on a food label are understood by consumers to be

making a single claim. This understanding is crucial because the act

requires that a nutrient content claim be made ``only if the

characterization of the level made in the claim uses terms which are

defined in regulations * * *.'' (Section 403(r)(2)(A)(i) of the act

(emphasis added).) In its petition, NFPA argues that there is nothing

in the act that defines a claim to mean individual label statements--as

opposed to the overall message conveyed by labeling for a product. The

petition stated that, in NFPA's view, a ``claim'' is properly viewed

under the statute as referring to the message about the level of a

particular nutrient in the food conveyed in the context of the entire

product labeling. NFPA maintained that, while the labeling should

include terms defined by FDA, other synonyms or implied statements

concerning the nutrient should be viewed as components of the single

labeling claim. FDA tentatively concludes that the use of unlisted

synonyms in the manner proposed will ensure that consumers understand

them to be part of a single nutrient content claim that uses terms

defined by regulation. As stated in its May 11, 1995, letter to NFPA,

however, the agency cannot finalize this rule unless it receives

evidence demonstrating that consumers understand the terms used in this

way.

FDA also recognizes that there may be some labels on which the

listed term is significantly more prominent than an unlisted synonym.

This would be the case, for example, if the listed term was made in a

``burst'' or in the statement of identity and the unlisted synonym was

used in a paragraph in smaller sized type. Such usage might occur if a

manufacturer wanted to use a variety of ways to express the level of a

nutrient in a discussion about the food. The agency tentatively finds

that, in this case, the level of the nutrient described by the listed

term would be clearly understood, and additional clarification next to

the smaller print on the same label would not be necessary. Therefore,

FDA is proposing in Sec. 101.13(r)(2)(ii)(B) that if the listed term is

more than twice as prominent on a label as the listed synonym, such

that the claimed nutrient level is clearly understood, e.g., a bold

faced listed term versus an unlisted synonym used only in a paragraph

in smaller sized type, the listed need not be placed adjacent to the

unlisted synonym. The agency requests comment on whether this approach

is consistent with a nonmisleading label.

The agency is also providing in proposed Sec. 101.13(r)(2)(iv) that

a listed term may not be used with an unlisted synonym to form a new

term, e.g., extra low, extra high, especially good source, or great

source. In its review of food

[[Page 66211]]

labels before the passage of the 1990 amendments, the Institute of

Medicine (IOM) stated that consumers were confused by the plethora of

terms on food labels and recommended that definitions of nutrient

levels for label claims be severely restricted (Ref. 2). The IOM

recommended that four levels be defined for explicit claims: Low, very

low, high and very high or their equivalents. The agency has

essentially done just that in defining, ``low,'' ``free,'' ``good

source'' and ``high.'' With the use of unlisted synonyms, the agency is

concerned that there may be instances when the use of unapproved

modifiers for these terms (e.g., ``extra low,'' ``extra high,''

``especially good source,'' ``great source'') would confuse consumers

by unjustifiably suggesting that there is a distinction between the

listed term with and without the modifier. To avoid this confusion, the

agency tentatively concludes that it is necessary to prohibit the use

of claims that consist of a term that modifies an existing listed term.

In the course of developing the definitions and other requirements

for the use of nutrient content claims, the agency made a diligent

effort to determine the various meanings and requirements of the

nutrient content claims it defined. In some cases the agency determined

that, in order for the label not to be misleading, it was necessary for

certain additional information to be conveyed to consumers along with

the claim. This information included referral or disclosure statements

(required by the statute), additional label statements such as

accompanying information for foods bearing relative claims

(Sec. 101.13(j)(2)), and other statements such as ``not a sodium free

food'' on a food bearing an ``unsalted'' claim that was not ``sodium

free'' (Sec. 101.61(c)(2)(iii)). Just as this information is necessary

for a listed term not to be misleading and for a label bearing such a

claim to provide full and relevant information to the consumer, the

agency tentatively concludes that such additional information is

equally important and necessary when unlisted synonyms are used.

Consequently, the agency is proposing in Sec. 101.13(r)(2)(iii) to

require that unlisted synonyms be used in conformance with all of the

requirements for the use of the listed terms.

The petitioners also requested that the agency permit the use of

unlisted synonyms with implied claims such as terms, statements, or

symbols. As with unlisted synonyms, FDA tentatively finds that this

concept may have some merit. However, the agency points out that

implied claims that are consistent with a listed term may currently be

used on a label. Therefore, the agency is not proposing further

provisions for the use of implied nutrient content claims.

B. Section 101.14(e)(6): The 10 Percent Nutrient Contribution

Requirement

In the Federal Register of January 6, 1993, FDA published a final

rule entitled ``Food Labeling: General Requirements for Health Claims

for Food'' (58 FR 2478) (hereinafter referred to as the 1993 health

claims final rule). Among other things, this rule requires that, to be

eligible to bear a health claim, a food other than a dietary supplement

contain 10 percent or more of the Daily Value (DV) for vitamin A,

vitamin C, iron, calcium, protein, or fiber, before any nutrient

addition (Sec. 101.14(e)(6)). As explained in that document, FDA

concluded that such a requirement was necessary to assure that the

value of health claims would not be trivialized or compromised by their

use on foods of little or no nutritional value. Furthermore, such a

requirement responded to Congress's intent that health claim provisions

consider the role of the nutrients in food in a way that will enhance

the chances of consumers constructing total daily diets that meet

dietary guidelines. Thus, foods bearing health claims should be

consistent with current dietary guidelines. Furthermore, the agency

concluded that fortification of foods of little or no nutritional value

for the sole purpose of qualifying that food for a health claim is

misleading, especially if foods such as confections, soda, and sweet

desserts are fortified to qualify for a health claim, because such

foods have been cited in dietary guidance as those that should be used

sparingly.

In the Federal Register of August 18, 1993 (58 FR 44036), FDA

published technical amendments to the health claim regulations in

response to comments that the agency received on the implementation

final rule (hereinafter referred to as the 1993 health claims technical

amendment). One of the comments stated that if a health claim petition

were submitted for the claim ``useful only in not promoting tooth

decay,'' virtually none of the sugar-free products on the market would

be eligible to bear the claim because of the 10 percent nutrient

contribution requirement.

In the 1993 health claims technical amendments, FDA acknowledged

that certain food products of limited nutritional value that have been

specially formulated relative to a specific disease condition, such as

dental caries, may be determined to be appropriate foods to bear a

health claim. The agency commented that its intention was to deal with

such situations within the regulations authorizing specific health

claims. Therefore, FDA amended Sec. 101.14(e)(6) to state that:

Except for dietary supplements not in conventional food form or

where provided for in other regulations in part 101, subpart E, the

food contains 10 percent or more of the Reference Daily Intake or

Daily Reference Value for vitamin A, vitamin C, iron, calcium,

protein, or fiber per reference amount customarily consumed prior to

any nutrient addition.

The terminology ``not in conventional food form'' was subsequently

deleted in the final rules pertaining to health claims for dietary

supplements published in the Federal Register on January 4, 1994 (59 FR

395).

The sugar alcohols proposal proposes such an exemption from the 10

percent nutrient contribution requirement.

Following publication of the health claims final rule, two trade

associations--NFPA and the ABA--submitted petitions to FDA requesting

that the agency revise the general requirements for health claims and

reconsider its decision regarding the 10 percent nutrient contribution

requirement. The NFPA petition argued that the 10 percent nutrient

contribution requirement precludes truthful, nonmisleading health

claims because it sets an arbitrary nutritional contribution a food

must make to the diet to qualify for any claim. Consequently, NFPA

argued, the 10 percent nutrient contribution requirement prohibits some

common fruits, vegetables, and other wholesome and nutritious foods

from making health claims. While NFPA agreed that a food bearing a

health claim should contain levels of the nutrient consistent with the

health claim, it contended that the lack of significant levels of other

nutrients should not prevent a food from bearing a health claim. NFPA

argued that if other nutrient levels are deemed to be material with

respect to consumers' understanding of a health claim, then such levels

should be disclosed in the Nutrition Facts panel.

Furthermore, NFPA contended that the 1993 health claims final rule

precludes truthful, nonmisleading claims because it prohibits a food

from satisfying the 10 percent nutrient contribution requirement

through fortification. NFPA stressed that even though fortification of

a food to support a health claim is material information that should be

disclosed in labeling, added and indigenous nutrients are equally

nutritious, and, therefore,

[[Page 66212]]

prohibiting fortified foods from bearing a health claim is not

justified.

NFPA requested that FDA amend Sec. 101.14(e) by revoking the

requirement that foods bearing a health claim contain 10 percent of the

DV of vitamin A, vitamin C, calcium, protein, iron, or fiber before any

nutrient addition, so that fruits, vegetables, and other nutritious

foods could bear health claims.

The ABA petition did not request that the agency revoke the 10

percent nutrient contribution requirement. Rather, it requested that

FDA modify the 10 percent nutrient contribution requirement to permit

health claims on certain enriched grain products. ABA contended that

while some enriched breads might meet the 10 percent nutrient

contribution requirement for fiber, most enriched grain products cannot

meet the 10 percent nutrient contribution requirement for any of the

six listed nutrients because they are precluded by the standards of

identity from containing 10 percent of the six listed nutrients. ABA

also stated that the standards of identity require specific nutrient

addition at levels that were established by FDA as optimal for reducing

the risk of certain diet-related diseases. These foods, in fact, have

been used for many years to improve the nutrition of U.S. consumers and

to reduce the risk of diet-related diseases. Therefore, ABA contended

that these foods are precisely the kinds of foods that should be

permitted to bear health claims.

ABA argued that the 10 percent nutrient contribution requirement

was obviously not intended to apply to foods that conform to the

standards of identity for enriched grain products because it precludes

virtually all enriched grain products from bearing health claims. It

contended that this exclusion is inconsistent with the basis of the

health claims because these foods are not only beneficial in reducing

the risk of diet-related diseases but, more importantly, are also

recommended in current dietary guidelines as foods whose consumption

should be increased to maintain a balanced and healthful diet. The

petition noted that the Food Guide Pyramid recommends that 6 to 11

servings of grain products be consumed per day. ABA contended that this

recommendation demonstrates the importance of including these foods in

the diet. ABA argued that the 10 percent nutrient contribution

requirement has had the unintended effect of precluding foods that FDA

concluded could appropriately bear a health claim from bearing the

claim. Thus, ABA requested that the agency amend Sec. 101.14(e) to

exempt from the 10 percent nutrient contribution requirement enriched

grain products that conform to a standard of identity in part 136, 137,

or 139, and bread that conforms to the standard of identity for

enriched bread in Sec. 136.115, except that it contains whole wheat or

other grain products not permitted under that standard.

In the alternative, ABA suggested that the agency expand the list

of nutrients that must be present at 10 percent to include complex

carbohydrates, niacin, or thiamin. Such action, the petition explained,

would permit enriched grain products to bear health claims because

these products are a significant source of such nutrients.

As a second alternative, ABA suggested that FDA amend the 10

percent nutrient contribution requirement to allow it to apply to a

daily consumption of grain products rather than to the nutrient profile

of a specific food.

FDA has fully evaluated and considered the arguments raised in both

petitions. FDA recognizes that the 10 percent nutrient contribution

requirement may have had the unintended effect of prohibiting health

claims on certain foods that could be beneficial for consumers and help

them to maintain a balanced and healthful diet. The agency is

concerned, however, that eliminating the 10 percent nutrient

contribution requirement will permit misleading health claims on foods

with little or no nutritional value such as candies and soft drinks or

will encourage overfortification of the food supply (e.g., vitamin or

mineral addition to soft drinks). The appearance of health claims on

such foods would be inconsistent with Congress's intent when it enacted

the health claims provisions. As discussed in the 1993 health claims

final rule, Congress enacted the health claims provisions of the 1990

amendments to not only protect consumers from health claims that are

not scientifically valid but also to help consumers maintain healthy

dietary practices by providing information that would be useful in

constructing total daily diets that meet current dietary guidelines.

Thus, an important part of the significance and benefit of health

claims is that they appear on foods that are compatible with current

dietary recommendations. (See H. Rept. 101-538, 101st Cong., 2d sess.

pp. 9-10 (1990).)

During the development of the health claims final rule, FDA

considered other alternatives that would ensure that health claims are

not trivialized or rendered meaningless by appearing on foods of little

or no nutritional value. For example, the agency considered prohibiting

health claims on specific foods, such as confections, soda, and snack

foods, based on the foods' categorization or characteristic use.

However, as fully discussed in the 1993 health claims final rule (58 FR

2478 at 2521), the agency was not persuaded that such action was in

keeping with the intent of the statute. The agency concluded that

Congress did not intend that specific foods that could be in general

use be prohibited from bearing a health claim. Thus, the agency

concluded that a prohibition on health claims for specific categories

of foods was not a viable option.

However, given the requirement in section 403(r)(3)(B)(iii) of the

act that a claim should enable the public to comprehend the information

in a claim and understand the relative significance of that information

in the context of a total daily diet, FDA concluded (as discussed in

the 1993 health claims final rule (58 FR 2478 at 2521-2522)) that it is

appropriate to provide a basis for health claims that takes into

account the nutritional contribution of the food beyond its role as a

source of calories. The agency noted that ``Congress intended that FDA

establish provisions of health claims regulations by considering the

role of the nutrients in food in a way that will enhance the chances of

consumers constructing total daily diets that meet dietary guidelines''

(Id. at 2521). Without such provisions, foods that are not compatible

with dietary guidelines could bear health claims. In addition to being

inconsistent with Congress's intent when it established the health

claim provisions, and section 403(r) of the act, claims intended to

promote the consumption of a food that is incompatible with dietary

guidelines would be misleading to consumers and, therefore, would be in

violation of section 403(a) (id.). Such claims would be misleading

because consumers would be purchasing the food, in part, to achieve a

more healthful diet, when, in fact, such foods are inconsistent with

dietary guidelines. Further, such claims could be damaging if consumers

are encouraged to replace wholesome and nutritious foods that are

recommended in dietary guidelines with these foods.

Thus, the agency concluded then, and reiterates now, that the 10

percent nutrient contribution requirement is a necessary component of

the health claims provisions to ensure that such claims appear on foods

that make a nutritional contribution to the diet and are consistent

with dietary guidelines. If the agency were to revoke this requirement,

it would have to establish

[[Page 66213]]

an alternative mechanism to ensure that health claims are not made on

inappropriate foods. The NFPA petition did not suggest any alternatives

to the 10 percent nutrient contribution requirement to preclude

misleading health claims on inappropriate foods.

The agency also tentatively concludes that the alternatives

suggested in the ABA petition would not ensure that health claims were

made only on foods that are consistent with dietary guidelines. Relying

on either of the two alternatives suggested in the ABA petition would

not adequately assist consumers in placing foods that bear health

claims in their proper dietary context.

The ABA's suggestion that the nutrients required to be present at

10 percent be expanded to include thiamin, niacin, or carbohydrates

would not encourage consumers to increase their intake of vitamins and

minerals that have been identified as those of continuing public health

significance. Public health concerns for deficient intakes of thiamin,

niacin, or carbohydrates have lessened considerably in the last 20

years, whereas the inadequate intakes of vitamin A, vitamin C, calcium,

and iron remain a public health concern especially because of the

possible association between several of these nutrients and the risk of

chronic disease. Furthermore, expanding the list of nutrients required

to be at 10 percent to include thiamin, niacin, or carbohydrates would

permit only certain foods to bear health claims, such as enriched

cereal grain products. Certain fruit and vegetable products that are

promoted in dietary guidelines but that are currently prohibited from

bearing health claims would still not be able to bear a health claim.

Consequently, the agency tentatively concludes that expanding the list

of nutrients would not sufficiently address the concern that the

current regulation precludes certain foods that contribute to a

healthful diet, and whose consumption is encouraged by the dietary

guidelines, from bearing health claims.

Likewise, permitting the 10 percent nutrient contribution

requirement to be based on the daily consumption of a food group would

not enhance the likelihood of consumers achieving dietary goals. In

fact, such a requirement would be contrary to dietary goals because it

would reduce the likelihood that a consumer would reach 100 percent of

the DV if daily consumption of an entire food group only supplies 10

percent of one of the listed nutrients. One reason for requiring that a

serving of the food provide 10 percent of one or more of the listed

nutrients is to assist the consumer in achieving daily intakes

recommended in current dietary guidelines. Permitting a food that does

not meet the 10 percent nutrient requirement to bear a claim on the

basis that the total daily consumption of foods from that category

would provide 10 percent of the nutrient would be inconsistent with one

of the basic principles of the requirement. Accordingly, the agency has

not been persuaded by the arguments raised in the petitions to propose

to eliminate the 10 percent nutrient contribution requirement, to

expand the list of nutrients that will qualify a food to bear a health

claim, or to allow the 10 percent nutrient requirement to apply to a

daily consumption of grain products rather than to the nutrient profile

of a specific food.

Regarding the request that FDA permit fortification to meet the 10

percent nutrient contribution requirement, the agency is concerned that

fortification of foods solely to bear a health claim could result in

deceptive or misleading labeling and, thereby, be in violation of

section 403(a) of the act. As fully addressed in the 1993 health claims

final rule (58 FR 2478 at 2522), fortification of a food of little or

no nutritional value for the purpose of bearing a health claim has the

great potential of misleading and confusing consumers if foods like

confections, soda, and sweet desserts are fortified to qualify for a

health claim when, at the same time, dietary guidance as contained in

the Food Guide Pyramid, for example, states that ``[T]hese foods

provide calories and little else nutritionally. Most people should use

them sparingly'' (Ref. 3). Indiscriminate fortification of such foods

with one nutrient would not make such foods consistent with dietary

guidelines. Consequently, FDA has not been persuaded that foods should

be permitted to be fortified to qualify to bear a health claim.

Accordingly, FDA is denying NFPA's request to permit fortification to

specifically qualify a food to bear a health claim.

The agency notes, as discussed in the 1993 health claims technical

amendments (58 FR 44036 at 44037), that some foods either have been

traditionally formulated in accordance with the fortification policy or

to meet standards of identity that include fortification and, in that

form, contain 10 percent or more of one of the six nutrients listed. In

such cases, the agency notes that the food would not be precluded by

Sec. 101.14(e)(6) from being fortified to qualify for a health claim.

Although the agency has not been persuaded that elimination of the

10 percent nutrient contribution requirement is in order, or that it

should permit fortification so that a food could qualify to bear a

health claim, the agency has been persuaded by the arguments raised in

the petitions that it should act to modify the 10 percent nutrient

contribution requirement. As stated above, the agency acknowledges that

the 10 percent nutrient contribution requirement has had the unintended

effect of precluding some foods that contribute to a healthful diet,

and whose consumption is encouraged by the dietary guidelines, from

bearing health claims. As discussed above, the agency's primary goals

in establishing the 10 percent nutrient contribution requirement were

to preclude foods of little or no nutritional value from bearing health

claims and, at the same time, to enhance the likelihood of consumers

constructing overall daily diets that conform to current dietary

guidelines.

FDA recognizes that precluding certain fruits, vegetables, and

grain products from bearing health claims because of the 10 percent

nutrient contribution requirement is contrary to that goal. The agency

agrees with the arguments raised in the petitions that certain fruits,

vegetables, and grain products that otherwise meet the requirements of

the specific health claim should be able to bear the claim even though

they do not contain 10 percent of one of the six listed nutrients

because these foods comprise a major part of a balanced and healthful

diet, and because current dietary guidance promotes consumption of

these foods. Moreover, diets high in fruits, vegetables, and grain

products have been associated with various specific health benefits,

including lower occurrence of coronary heart disease and of some

cancers (Refs. 4 and 5) and therefore, are exactly the types of foods

that should be included in the diet to reduce the risk of specific

diet-related diseases. Precluding such foods from bearing health claims

could confuse consumers and undermine the utility of health claims.

Furthermore, the foods described in the petitions are not the types

of foods FDA intended to preclude from bearing health claims when it

established the 10 percent nutrient contribution requirement. In fact,

these foods can contribute significantly to a balanced and healthful

diet and to achieving compliance with dietary guidelines even though

they do not meet the 10 percent nutrient contribution requirement.

Consequently, the agency

[[Page 66214]]

tentatively concludes that fruit and vegetable products comprised

solely of fruits and vegetables, enriched grain products that conform

to a standard of identity, and bread that conforms to the standard of

identity for enriched bread except that it contains whole wheat or

other grain products not permitted under that standard, that do not

meet the 10 percent nutrient contribution requirement but that meet all

other aspects of the health claim should be permitted to bear a health

claim. Accordingly, the agency is proposing to amend Sec. 101.14(e)(6)

to exempt these products from the 10 percent nutrient contribution

requirement.

The agency is proposing to limit the exemption for fruit and

vegetable products to those products comprised solely of fruits and

vegetables because it is concerned that permitting health claims on

fruit and vegetable products that do not contain 10 percent of one of

the six listed nutrients, but that contain ingredients that may raise

the level of certain other nutrients, such as fat, cholesterol, and

sodium, would be inconsistent with the purpose of the health claim and

incompatible with current dietary guidelines. While the agency

recognizes that fruit and vegetable products with added syrups, sauces,

and other ingredients that have increased levels of fat, cholesterol,

or sodium have an appropriate place in the diet, the agency tentatively

concludes that to exempt these products from the 10 percent nutrient

contribution requirement would be to promote the consumption of foods

that do not fall within the recommendations in dietary guidelines.

Accordingly, the agency is not prepared to extend the exemption to

these products. However, FDA requests comment on whether the exemption

proposed in this document should be extended to include fruit and

vegetable products with added oils, sodium, sauces, syrups, or other

ingredients.

The agency also requests comment on whether other foods, for

example, other types of grain products such as breakfast cereals,

should be exempt from the 10 percent nutrient contribution requirement.

The agency advises that comments submitted in support of extending this

exemption to other foods should provide valid data and sound

justification for exempting such foods from the 10 percent nutrient

contribution requirement. If the comments persuade the agency that such

foods are being unfairly precluded from bearing health claims, and that

the foods are consistent with the intent of the health claims, the

agency will consider including such foods in the exemption provided in

any final regulation based on this proposal.

C. Abbreviated Health Claims

Current Sec. 101.14(d)(2)(iv) mandates that all information

required to be included in the claim appear in one place without other

intervening material. The current rule, however, does permit a

reference statement ``See-------- for information about the

relationship between-------- and--------,'' with the blanks filled in

with the location of the labeling containing the health claim, the name

of the substance, and the disease or health-related condition (e.g.,

``See attached pamphlet for information about calcium and

osteoporosis'') with the complete health claim appearing elsewhere on

the other labeling. The current rule also permits the use of graphic

material, such as a symbol that constitutes an expressed or implied

health claim, to be used on the label or labeling of the product

provided that it is accompanied by the complete claim, an abbreviated

claim, or a referral statement (Sec. 101.14(d)(2)(iv)).

In the preamble to its 1993 health claims final rule, the agency

stated that it did not believe that it is appropriate to use

abbreviated health claims as referral statements (58 FR 2478 at 2512).

The agency was concerned that an abbreviated claim did not include

facts that are material in light of the representation that is made and

that are necessary to understand the claim in the context of the daily

diet. The agency was concerned that such confusion is possible

``whenever the full health claim information appears in a location

different from that of the reference statement and is especially likely

to occur when a multiplicity of labeling is associated with a product''

(Id.). The agency then described the situation where the grocer

displays an abbreviated claim on a display (labeling) near the product

but only puts the full claim on a billboard in a far corner of the

store (labeling) (id.).

In its petition, NFPA requested that the agency reconsider this

position and permit greater latitude in constructing and presenting

health claims. More specifically, the petition requested that FDA

permit abbreviated health claims that are accompanied by a referral

statement directing the consumer to the label panel where the complete

health claim appears.

The agency has no desire for its regulations to unnecessarily stand

in the way of the use of health claims and the presentation of the

important information contained therein. While health claims are

currently being used on the label and in labeling, the agency would

like to see them used more extensively. Consequently, the agency agreed

to initiate rulemaking in this area. The agency stated, however, that

it must have assurance that the claims will be presented in a

scientifically valid, truthful, and nonmisleading manner.

FDA notes that in this document the agency is proposing to provide

the basis for shorter health claims by making optional some of the

elements that it has required to be included in claims. If those

changes are finalized, many of the complete claims will be brief enough

to permit their use on the principal display panel. For example, a

claim for sodium and hypertension could be made in 12 words: ``Diets

low in sodium may reduce the risk of high blood pressure.'' Most other

claims would be of a similar length. The agency believes that these

shortened claims will, for the most part make this issue moot.

Nevertheless, the agency recognized that some claims may still remain

somewhat complex.

In those cases where the complete health claim remains long and

somewhat complex, the agency recognizes that there may be a need to

permit a shortened version of the claim on the principal display panel.

Although the entire health claim contains important information

necessary for consumers to fully understand the subject substance-

disease relationship, the agency recognizes that a short message that

captures the consumer's attention will facilitate use of the claim. As

a result, the communication of formation will assist consumers in

achieving healthful dietary practices.

The agency tentatively concludes that the use of an abbreviated

health claim on the principal display panel is consistent with the act.

The full health claim includes information required under section

403(a) and 403(r)(3)(B)(iii) of the act. Section 403(r)(3)(B)(iii)

requires that the complete health claim ``enable[] the public to

comprehend the information provided in the claim and to understand the

relative significance of such information in the context of a total

daily diet.'' Section 403(a) of the act requires only that a claim not

be false and misleading. FDA has long required that all information

that is necessary to make the claim truthful and not misleading appear

in one place, without any intervening material. (See, e.g., United

States v. An Article of Food * * * ``Manischewitz * * * Diet Thins'',

377 F. Supp. 746 (E.D. New York 1974)). However, there is nothing in

the act that would require that information required under section

403(r)(3)(B)(iii) appear as

[[Page 66215]]

part of the claim each time it is presented on the label.

Thus, an abbreviated health claim that is a scientifically valid

representation of the relationship between a substance and a diet-

related disease may be permissible under section 403(a) of the act if

it is truthful and not misleading. If such an abbreviated claim

includes a prominent and immediately adjacent reference to the full

claim elsewhere on the label, the requirements of section 403(a) and

(r)(3)(B)(iii) of the act would be fulfilled. Consequently, the agency

is proposing to amend Sec. 101.14(d)(2)(iv). In addition to permitting

the current reference statement to the full claim

(Sec. 101.14(d)(2)(iv)(A)), the agency is proposing to permit an

abbreviated health claim to be used on the principal display panel of

the label provided that it is accompanied by a reference statement to

the complete health claim on the same label or in the same labeling

(proposed Sec. 101.14(d)(2)(iv)(B)).

It is vital to compliance with the act that the complete claim

appear elsewhere on the same label or in the same labeling as the

abbreviated claim. For example, as discussed below for the calcium and

osteoporosis health claim, the agency is concerned that consumers might

be less likely to read the full health claim if an abbreviated claim

appears on the principal display panel of a label, and the full health

claim appears in a separate brochure that accompanies the product.

The agency is also proposing to require that the reference

statement be prominent and in immediate proximity to the abbreviated

claim. The agency notes, of course, that if the proposed provision is

adopted, an abbreviated claim could not be used unless the food meets

the criteria necessary to make the complete health claim.

As stated above, in the section D.IV. of this document, the agency

is proposing to amend the regulations in subpart E of part 101, where

appropriate, to set forth the elements that are required to ensure that

an abbreviated health claim complies with section 403(a) of the act. As

stated above, provision for an abbreviated claim will not be needed for

most of the nutrient-disease relationships about which FDA has

authorized claims if the revisions proposed in this document are

adopted. Consumers may benefit, however, from abbreviated claims for a

few of the longer, more complicated claims, such as those for calcium/

osteoporosis and folic acid/neural tube defects.

The agency strongly emphasizes that the diet-disease relationship

may not be overstated. Even with a prominent referral to the full

claim, the abbreviated claim must not overemphasize the importance of

the substance in the diet-disease relationship or in the total daily

diet. The concept of risk reduction must be accurately conveyed.

The agency notes that some of the diet-disease relationships may

already be well-known by consumers. Therefore, nutrient content claims

such as ``low sodium'' and ``reduced cholesterol'' on the principal

display panel and elsewhere on the label may serve as a reminder of the

diet-disease relationship and provide a way to market a product for its

contribution to a healthy diet.

FDA encourages the use of all authorized claims by the food

industry in order to educate consumers about the importance of a

healthy diet. The agency believes that the proposed changes to

Sec. 101.14(d)(2)(iv) will result in increased use of the authorized

health claims and, consequently, will fulfill the legislative intent to

educate the public about diet-disease relationships.

D. Specific Requirements for Health Claims

To date, FDA has authorized eight health claims that are codified

in the Code of Federal Regulations, Title 21, subpart E of part 101

(Secs. 101.72 to 101.79). Among the actions requested by NFPA in its

petition is one to ``* * * modify the regulations in subpart E of part

101 prescribing the content of authorized health claims so that they

constitute `safe harbors' rather than requirements for claims; * * *.''

To accomplish this request, NFPA requested that the health claims

regulations be modified to permit simplified, nondeceptive claims that

are likely to be more easily understood. NFPA contended that the

specific health claims regulations contained in subpart E of part 101

include several provisions that prescribe the content and form of

health claims to an extent that far exceeds that necessary to ensure

that claims are truthful and not misleading. Mentioned as an example

was that some regulations require claims to include references to

specific nondietary factors even though, in NFPA's view, this

information is unnecessary to ensure a claim is stated in a truthful,

nonmisleading manner. Cited as illustrative of the nature of the

problem was the model claim from the calcium/osteoporosis regulation

(Sec. 101.72(e)) containing all required elements:

Regular exercise and a healthy diet with enough calcium helps

teen and young adult white and Asian women maintain good bone health

and may reduce their high risk of osteoporosis later in life.

Each of the other regulations authorizing claims in subpart E of part

101 was identified as requiring similar information.

NFPA requested that the regulations in subpart E of part 101

governing the specific information that must appear in a health claim,

and the circumstances in which a claim could be used, be amended.

Where, for example, Sec. 101.14(d)(2)(i) requires that labeling

statements about a health claim be based on, and consistent with, the

conclusions set forth in the regulations in subpart E of part 101, NFPA

recommended amending Sec. 101.14(d)(2)(i), along with Sec. 101.14(d)(1)

and the rest of (d)(2), so that such statements are objective and

either consistent with applicable guidelines set forth in subpart E of

part 101, or a reasonable basis for the claim is otherwise

substantiated. The petitioner contended that such changes would operate

to allow truthful, nonmisleading health claims that either omit

information currently required under the regulations (e.g., nondietary

information) or that include other useful information not expressly

authorized by the regulations.

Responding to NFPA in the May 11, 1995, letter, FDA acknowledged

that, although use of health claims in food labeling has increased over

the period of time that they have been in effect, the number of

products bearing such claims is not as great as the agency had

anticipated. Because of the importance of the information conveyed to

consumers by health claims, the agency stated that it would review the

authorizing regulations to determine whether they contain any

unnecessary barriers to the use of the claims and, if so, take steps to

remove those barriers. FDA stated that, as part of this assessment, it

would conduct a review of what are referred to as ``required elements''

in each of the eight authorized health claims to determine whether any

of them are unnecessary or can be made optional and initiate rulemaking

to propose any changes identified in its internal review.

The eight authorized health claims in subpart E of part 101 are

codified following the same format. Thus the ``required elements'' for

each claim are contained in paragraph (c) of the respective regulation

under the heading ``Requirements.'' For example, specific requirements

that apply to the calcium/osteoporosis health claim are contained in

Sec. 101.72(c)(2)(i)(A) through (c)(2)(i)(E).

[[Page 66216]]

The agency has reviewed all of the required elements in the eight

authorized claims codified in subpart E of part 101. This document

presents the results of this review for the following seven claims:

Sec. 101.72 on calcium and osteoporosis; Sec. 101.73 on dietary lipids

and cancer; Sec. 101.74 on sodium and hypertension; Sec. 101.75 on

dietary saturated fat and cholesterol and risk of coronary heart

disease; Sec. 101.76 on fiber-containing grain products, fruits, and

vegetables and cancer; Sec. 101.77 on fruits, vegetables, and grain

products that contain fiber, particularly soluble fiber, and risk of

coronary heart disease; and Sec. 101.78 on fruits and vegetables and

cancer. The health claim on folate and neural tube defects

(Sec. 101.79) will be dealt with separately but in a manner consistent

with the review of the other health claims.

Since the final rules on the seven claims addressed in this

document were published on January 6, 1993 (58 FR 2537 to 2849), new

data have become available allowing FDA to reconsider the need for some

information that, at the time the specific health claim regulations

were issued, was considered necessary to preclude a claim from being

misleading. Most notable among these data are two documents, one a

National Institutes of Health (NIH) consensus statement on optimal

calcium intake (hereinafter referred to as the 1994 consensus

statement) and the other an FDA report on consumer understanding of

health claims (hereinafter referred to as the 1995 consumer report)

(Refs. 6 and 7, respectively).

1. The Calcium/Osteoporosis Health Claim

The 1994 consensus statement is the result of the Consensus

Development Conference on Optimal Calcium Intake convened by NIH on

June 6 through 8, 1994, which brought together experts in public

education and different biomedical sciences dealing with osteoporosis

and bone and dental health. Directly relevant to the calcium/

osteoporosis health claim, this conference addressed questions and

provided recommendations on optimal calcium intake for various

population segments, on important cofactors for achieving optimal

intake, on the risks associated with increased intake, on the best ways

to attain optimal intake, and on the public health strategies that are

available or are needed to implement optimal calcium intake

recommendations.

The 1995 consumer report is part of FDA's ongoing review of its

regulations governing health claims. The report evaluated consumer

understanding of four health claims (dietary lipids and cancer, fruits

and vegetables and cancer, calcium and osteoporosis, and folate and

neural tube defects) and consumer reaction to possible variations on

the messages. The report describes the content, the manner of

presentation, and the results of a consumer survey of knowledge about

the four health claims mentioned above among consumer groups at

eastern, central, and western locations in the United States.

For the calcium/osteoporosis health claim, the first required

element is contained in Sec. 101.72(c)(2)(i)(A) and provides that:

The claim makes clear that adequate calcium intake throughout

life is not the only recognized risk factor in this multifactorial

bone disease by listing specific factors, including sex, race, and

age that place persons at risk of developing osteoporosis and

stating that an adequate level of exercise and a healthful diet are

also needed.

The effect of presenting the information required by this element is to

convey the message that, for any individual, several factors define the

disease risk.

The focus of the 1994 consensus statement is, as stated in its

title, optimal calcium intake for promotion of public health. The first

of several significant conclusions in the report is that a large

percentage of Americans fail to meet currently recommended guidelines

for optimal calcium intake. Because of the need to correct this public

health shortfall and to improve bone health in the United States,

thereby reducing the risk of osteoporosis, FDA tentatively concludes

that a singular focus on achieving and maintaining adequate calcium

intake as a required element in the calcium/osteoporosis health claim

is important.

Accordingly, FDA is proposing to simplify Sec. 101.72(c)(2)(i)(A)

by limiting the requirement to a balanced statement that reflects the

importance of the essential nutrient calcium over a lifetime in a

healthful diet to reduce osteoporosis risk, but that does not imply

that calcium is the only risk factor for the development of

osteoporosis. To this end, proposed Sec. 101.72(c)(2)(i)(A) states that

the claim must make clear that adequate calcium intake as part of a

healthful diet throughout life is essential to reduce the risk of

osteoporosis.

FDA has included the reference to a ``healthful diet'' in proposed

Sec. 101.72(c)(2)(i)(A) for consistency with the general requirement in

Sec. 101.14(d)(2)(v) that ``the claim enable[ ] the public * * * to

understand the relative significance of such information [in this case,

the relationship between calcium and osteoporosis] in the context of a

total daily diet.'' The effect of adequate calcium intake can only be

realized if the calcium is a part of a healthy diet that provides all

essential and other nutrients to optimize nutritional health status.

The proposed revision of Sec. 101.72(c)(2)(i)(A) emphasizes the

most important risk factor in the development of osteoporosis on the

label of a food product, i.e., adequacy of dietary calcium intake.

Nevertheless, the agency is concerned that such a claim could lead

consumers to believe that adequacy of dietary calcium intake is the

only risk factor for the disease. In the proposal to authorize the

calcium/osteoporosis health claim, the following was stated:

Calcium intake is not the only recognized risk factor in the

development of osteoporosis. Other factors include a person's sex,

race, hormonal status, family history, body stature, level of

exercise, general diet, and specific life style choices, such as

smoking and excess alcohol consumption.

(56 FR 60689 at 60698, November 27, 1991). Based on that information in

part, Sec. 101.72(c)(2)(i)(A) requires a listing of several specific

risk factors, in addition to dietary calcium intake, in the calcium/

osteoporosis health claim.

As stated above, however, FDA acknowledges that the number of food

products bearing health claims is not as great as the agency had

anticipated. FDA is concerned that manufacturers have been disinclined

to use lengthy health claims on food labels, and that too many words

will detract from the central consumer message of the claim. As a

result, FDA is concerned that health claims like the calcium/

osteoporosis claim will continue to be infrequently used, and that the

benefits of communicating information on diet-disease relationships

through such claims will not be realized.

Because of these concerns, the agency has reevaluated the

requirement in Sec. 101.72(c)(2)(i)(A) that a calcium/osteoporosis

health claim ``* * * list[ ] specific factors, including sex, race, and

age that place persons at risk of developing osteoporosis and stat[e]

that an adequate level of exercise * * * [is] also needed.'' Given the

consensus statement's central focus on optimal calcium intake and the

agency's desire to make health claims as useful and useable as

possible, FDA is proposing to replace the requirement in

Sec. 101.72(c)(2)(i)(A) that specific risk factors and the need for an

adequate level of exercise be stated in any claim with the more simple

requirement that the claim not imply that adequate dietary calcium

intake is the only recognized risk factor for a reduced risk

[[Page 66217]]

of osteoporosis. This revision will ensure that the scientific validity

of claims about osteoporosis is preserved by recognizing the

multifactorial nature of this disease without adding words to the

claim.

In concert with the proposed change in Sec. 101.72(c)(2), the

agency is proposing to redesignate Sec. 101.72(d)(2) as paragraph

(d)(5) and to add a new paragraph (d)(2) that provides for the

provision of the following information from current

Sec. 101.72(c)(2)(i)(A) as optional information:

The claim may list specific risk factors for osteoporosis,

identifying them among the multifactorial risks for the disease.

Such factors include a person's sex, age, and race. The claim may

state that an adequate amount of exercise is also needed to reduce

risk for the disease.

The 1995 consumer report identified the calcium/osteoporosis model

health claim as the one most actively disliked (Ref. 7). This dislike

most likely arises primarily from a misunderstanding one of the

concepts required in Sec. 101.72(c)(2)(i)(B), specific identification

of the populations at particular risk for the disease. The current

regulation states:

The claim does not state or imply that the risk of osteoporosis

is equally applicable to the general United States population. The

claim shall identify the populations at particular risk for the

development of osteoporosis. These populations include white (or the

term ``Caucasian'') women and Asian women in their bone forming

years (approximately 11 to 35 years of age or the phrase ``during

teen or early adult years'' may be used). The claim may also

identify menopausal (or the term ``middle-aged'') women, persons

with a family history of the disease, and elderly (or ``older'') men

and women as being at risk.

The 1995 consumer report states that minority women were unanimous

in objecting to the inference that black American women do not need

calcium. Accordingly, minority participants questioned the accuracy of

the information. All of the survey participants recognized that calcium

is essential for everyone. Although there was some recognition based on

prior knowledge that younger women need to be concerned about

osteoporosis, no participant thought the model claim communicated that

concept very well. For these and other reasons, older women tended to

dismiss the model claim as incorrect.

The agency did not intend that the calcium/osteoporosis health

claim imply that calcium is not needed by any individual or specific

population. Given that calcium is essential for every person, the

agency attempted to craft requirements for presenting this disease

claim in a truthful, nonmisleading, and scientifically valid manner. In

reviewing the scientific data supporting the claim, including the

incidence of low-trauma bone fracture in the elderly, FDA stated in the

preambles to the calcium/osteoporosis proposed and final rules (56 FR

60689 and 58 FR 2665, respectively) that those individuals in the

general population at greatest risk of developing osteoporosis, and for

whom the health claim would have greatest benefit, include Caucasian

and possibly Asian women and adolescent girls and young adult women

between 11 and 35 years of age. For this and other reasons, a

requirement for identifying these high risk groups was included in

Sec. 101.72(c)(2)(i)(B). In identifying those at highest risk, there

was no intent by the agency to imply that other consumers are risk

free.

The 1994 consensus statement is silent in ascribing relative risk

for osteoporosis on the basis of race or ethnicity of population

groups. For adolescents and young adults of both sexes, 11 through 24

years of age, the optimal calcium requirement is given as a range of

1,200 to 1,500 milligrams (mg) of calcium daily. The report says the

following about a subset of this population, 12 to 19 year old females:

Importantly, population surveys of girls and young women 12-19

years of age show their average calcium intake to be less than 900

mg/day, which is well below the calcium intake threshold. The

consequences of low calcium intake during this crucial period of

rapid skeletal accrual raise concerns that achievement of optimal

peak adult peak bone mass may be seriously compromised. Special

education and public measures aimed at improving dietary calcium

intake in this age group are essential.

(Ref. 6.)

FDA tentatively concludes that greater use in food labeling of the

calcium/osteoporosis health claim, articulated in a manner that will be

accepted and followed by consumers, can help support significant

strides in improving calcium intake in all segments of the U.S.

population. Accordingly, the agency is proposing to revise

Sec. 101.72(c)(2)(i)(B) in several ways.

First, it is proposing to revise Sec. 101.72(c)(2)(i)(B) by

removing the requirement to identify by race those populations at

particular risk for the development of osteoporosis. In neither the

statement cited above nor elsewhere in the 1994 consensus statement is

any racial or ethnic segment among girls and young women 12 to 19 years

of age identified as being more at risk for the consequences of a less

than optimal calcium intake. The 1994 NIH consensus statement found

that the recommendation for optimal nutrient requirements for any

particular age/sex population segment to forestall the impact of a

degenerative disease applies to all members of that segment, although

not necessarily to the same degree for everyone. Thus, the agency is

proposing not to require mention of race or ethnicity as a required

element but to permit such information as an option since it is useful

and important to those to whom it applies.

Nevertheless, retention of teen and young adult women, irrespective

of race or ethnicity, as the focus of the claim is important because,

as stated succinctly in the 1994 consensus statement:

Two important factors that influence the occurrence of

osteoporosis are optimal bone mass attained in the first two or

three decades of life and the rate at which bone is lost in later

years.

Failure to attain optimal bone mass during the bone-forming years

of adolescence and early adulthood is a loss that cannot be recovered

during middle age or later in life (Ref. 6). Once peak adult bone mass

is reached at about age 25, bone turnover is stable in men and women

such that bone formation and bone resorption (breakdown) are balanced.

In women, resorption rates increase, and bone mass declines, beginning

with the fall in estrogen production that is associated with the onset

of menopause. Unlike hormone replacement therapy, supplemental calcium

during this initial phase will not slow the decline in bone mass

attributable to estrogen deficiency. The effects of calcium in reducing

the rate of bone loss can be shown more clearly in postmenopausal women

after the period when the effects of estrogen deficiency are no longer

dominant (i.e., about 10 years after menopause).

Osteoporosis affects more than 25 million people in the United

States and is the major underlying cause of bone fractures in

postmenopausal women and the elderly (Ref. 6). Given this tremendous

cost to public health, it is essential that the health claim on calcium

and osteoporosis inform consumers, particularly those at great risk for

the disease, of the importance of adequate calcium intake throughout

life for attaining peak adult bone mass and for reducing the rate of

bone resorption or loss, two processes that occur at different periods

over a lifetime.

Thus, FDA is proposing to retain the requirement in

Sec. 101.72(c)(2)(i)(B) that the claim not suggest that the risk of

osteoporosis applies equally to the general U.S. population. However,

it is proposing to remove the required

[[Page 66218]]

reference to any racial or ethnic group in identifying the at-risk

population. The agency is proposing to identify this population in the

following way:

* * * The claim shall identify the population at particular risk

for the development of osteoporosis as women in their bone forming

years from approximately 11 to 35 years of age. An optional

statement that further characterizes this and other populations at

risk for developing osteoporosis may be made in accordance with

paragraph (d)(3) of this section.

FDA is proposing to permit identification of Caucasian women and

Asian women as among those at particular risk for the disease as

optional information, along with other information from

Sec. 101.72(c)(2)(i)(B), in new Sec. 101.72(d)(3). While the 1995

consumer report (Ref. 7) found evidence that some consumers could be

misled by references in the calcium/osteoporosis health claim to

Caucasian and Asian women, FDA tentatively concludes that, if properly

qualified, this information could be helpful in informing such women

who may be unaware of their risk of developing this disease. By

providing for this information as an optional element in

Sec. 101.72(d), the agency is attempting to encourage manufacturers to

use this information in formats where the message can be phrased in

enough detail to clarify its meaning. For example, ``while all women

may be at risk of osteoporosis, Caucasian and Asian women are

particularly at risk,'' may be understood and not rejected by

consumers. While this statement provides more detail than seems to be

necessary in the basic health claim, this information could be useful

in a longer discussion of calcium and osteoporosis, for example in a

paragraph format on a large label or in a pamphlet. The agency requests

comment, and is particularly interested in data, on whether its

tentative view that consumer understanding would be helped is correct.

Section 101.72(c)(2)(i)(C) established a requirement for

identifying the mechanism whereby adequate dietary calcium over a

lifetime should reduce the risk of osteoporosis:

The claim states that adequate calcium intake throughout life is

linked to reduced risk of osteoporosis through the mechanism of

optimizing peak bone mass during adolescence and early adulthood.

The phrase ``build and maintain good bone health'' may be used to

convey the concept of optimizing peak bone mass. When reference is

made to persons with a family history of the disease, menopausal

women, and elderly men and women, the claim may also state that

adequate calcium intake is linked to reduced risk of osteoporosis

through the mechanism of slowing the rate of bone loss.

The agency concluded in developing this requirement that it is

important for consumers to have a basic understanding of the biological

and physiological mechanisms by which adequate dietary intake of

calcium achieves a reduced risk of osteoporosis. However, information

developed since the regulation was published indicates that a health

claim may not be the best way to provide this information. The 1995

consumer survey (Ref. 7) found that, because participants had learned

elsewhere that calcium intake is related to general bone health, they

thought the food label was not the right means for conveying this

information. In addition, this awareness by consumers that calcium's

ability to ``build and maintain good bone health'' is the mechanism

whereby risk of osteoporosis is reduced, raises a question as to

whether there is a need to state that fact in a health claim. In the

interest of streamlining the claim, therefore, FDA is proposing to make

the statement of the mechanism by which calcium intake affects the risk

of osteoporosis optional information. The agency is proposing to move

Sec. 101.72(c)(2)(i)(C) to Sec. 101.72(d)(4), changing only the word

``shall'' to ``may''.

Section 101.72(c)(2)(i)(D) requires that:

The claim does not attribute any degree of reduction in risk of

osteoporosis to maintaining an adequate calcium intake throughout

life;

This paragraph is consistent with requirements in regulations for all

other authorized claims that no attribution to degree of risk reduction

for the respective disease or health-related condition be made in

reference to the nutrient or substance that is the subject of the claim

(see, for example: Secs. 101.73(c)(2)(i)(E), 101.74(c)(2)(i)(D),

101.75(c)(2)(i)(D), 101.76(c)(2)(i)(E), 101.77(c)(2)(i)(G),

101.78(c)(2)(i)(E), and 101.79(c)(2)(i)(F).

Unlike these other regulations, Sec. 101.72 does not contain an

express requirement that the claim state that adequate calcium intake

throughout life ``may'' or ``might'' reduce the risk of osteoporosis

(see, for example, paragraphs (c)(2)(i)(A) in Secs. 101.73 through

101.79). However, it is clear that FDA also intended that this

requirement apply to the calcium/osteoporosis health claim. This

intention may be inferred from the two model health claims that use the

term ``may'' in relating calcium intake with a reduction in risk of

osteoporosis. Accordingly, the agency is proposing to revise

Sec. 101.72(c)(2)(i)(D) and redesignate it as Sec. 101.72(c)(2)(i)(C)

to read as follows:

The claim does not attribute any degree to which maintaining

adequate calcium intake throughout life may reduce the risk of

osteoporosis;

This proposed revision retains the prohibition against attributing the

degree to which adequate calcium intake is associated with a reduced

risk for osteoporosis while introducing the concept that, because of

the multifactorial nature of the disease, maintenance of an adequate

calcium intake throughout life may reduce risk of developing the

disease.

Section 101.72(c)(2)(i)(E) contains the conditional requirement

that a calcium/osteoporosis health claim include a statement that

reflects the limit on the benefit derived from dietary calcium intake

as follows:

The claim states that a total dietary intake greater than 200

percent of the recommended daily intake (2,000 milligrams (mg) of

calcium) has no further known benefit to bone health. This

requirement does not apply to foods that contain less than 40

percent of the recommended daily intake of 1,000 mg of calcium per

day or 400 mg of calcium per reference amount customarily consumed

as defined in Sec. 101.12(b) or per total daily recommended

supplement intake.

Most conventional foods and many calcium-fortified foods do not

exceed the threshold of 40 percent of the DV for calcium for adults and

children 4 or more years of age and, therefore, do not trigger the

required use of the statement in Sec. 101.72(c)(2)(i)(E). Dietary

supplements containing calcium, particularly single nutrient

supplements containing 500 or 600 mg of calcium per tablet, exceed the

threshold and are therefore required to bear the statement as part of a

health claim. The Dietary Supplement Health and Education Act of 1994

(the DSHEA) (Pub. L. 103-417) was enacted on October 25, 1994, and

amends the act (Ref. 8). Among the findings of Congress for this new

law regarding the benefits of dietary supplements to health promotion

and disease prevention is one that identifies a link between ingestion

of certain nutrients or dietary supplements and reduced risk for

several chronic diseases including osteoporosis. Another finding states

that the Federal Government should not take any actions to impose

unreasonable regulatory barriers limiting or slowing the flow of safe

products and accurate information to consumers.

Among the issues addressed in the 1994 consensus statement is the

question of the ways by which optimal calcium intake may be attained.

The

[[Page 66219]]

document draws the following conclusion:

The preferred source of calcium is through calcium-rich foods

such as dairy products. Calcium-fortified foods and calcium

supplements are other means by which optimal calcium intake can be

reached in those who cannot meet this need by ingesting conventional

foods.

The agency has taken into consideration the expressed intent of the

DSHEA and this finding from the 1994 consensus statement and

tentatively concludes that revision of Sec. 101.72(c)(2)(i)(E) is in

order. The agency is proposing to raise the threshold for the required

statement from 400 to 1,500 mg of calcium, along with other changes.

With regard to adverse effects and the risks associated with

increased levels of calcium intake, the 1994 consensus statement states

the following:

Even at intake levels of less than 4 g/day, certain otherwise

healthy persons may be more susceptible to developing hypercalcemia

or hypercalciuria. Likewise, subjects with mild or subclinical

illnesses marked by dysregulation of 1,25-dihydroxyvitamin D

synthesis (e.g., primary hyperparathyroidism, sarcoidosis) may be at

increased risk from higher calcium intakes. Nevertheless, in

intervention studies (albeit of relatively short duration--less than

4 years), no adverse effects of moderate supplementation up to 1500

mg/day have been reported.

(Ref. 6.)

The same document concludes that daily calcium intake, up to a

total of 2,000 mg, appears to be safe in most individuals (Ref. 6). For

major segments of the U.S. population the 1994 consensus statement

identifies an optimal calcium requirement of either 1,500 mg or a range

of 1,200 to 1,500 mg of calcium per day. These population groups

include adolescents and young adults 11 to 24 years of age, pregnant

and lactating women, women over 50 (postmenopausal) who are not on

estrogens, and men over 65 years of age (Ref. 6). Therefore, the agency

tentatively finds that a level of 1,500 mg of calcium as the proposed

threshold for the statement in Sec. 101.72(c)(2)(i)(E) is not only

consistent with current recommendations for dietary calcium intake but

is also well within a range that is not known to cause adverse effects.

The agency is consequently proposing to require that the statement

of limited benefit appear only on foods that provide more than 1,500 mg

of calcium per day. FDA has expressed this proposed threshold level as

a percentage of the Daily Values (DV's) for adults and children 4 or

more years of age and for pregnant or lactating women. The agency notes

that the calcium DV's for adults and children 4 or more years of age

and for pregnant or lactating women have not changed and are 1,000 and

1,300 mg, respectively. (See Sec. 101.9(c)(8)(iv) and 58 FR 2206 at

2213.) The agency intends to redesignate this requirement as

Sec. 101.72(c)(2)(i)(D).

A common form of a calcium dietary supplement in the marketplace is

as a tablet containing either 500 or 600 mg of calcium as the sole

nutrient with directions for use in labeling that recommend an intake

of one or two tablets per day. A health claim in the labeling of such a

product would not require the additional statement in proposed

Sec. 101.72(c)(2)(i)(D). FDA tentatively concludes that this proposed

change is consistent with the recommendation from the 1994 consensus

statement on dietary sources for this nutrient.

For consistency with the proposed revisions in Sec. 101.72(c) and

(d), FDA has revised the model health claims in proposed

Sec. 101.72(e). FDA has used the phrase ``Especially for teen and young

adult women'' in example 1, which sets out how a claim that conforms

with Sec. 101.72(c) might look to reflect the effects on the risk of

developing osteoporosis that may be realized by this population segment

without implying that adequate calcium intake is without benefit for

others.

The agency solicits comment on the proposed revisions to the

calcium/osteoporosis health claim and is particularly interested in

data on consumer understanding of this claim, and how such

understanding can be improved.

2. Other Health Claims

A common requirement in the authorized claims for dietary fat and

cancer (Sec. 101.73); sodium and hypertension (Sec. 101.74); dietary

saturated fat and cholesterol and risk of coronary heart disease

(Sec. 101.75); fiber-containing grain products, fruits, and vegetables

and cancer (Sec. 101.76); fruits, vegetables, and grain products that

contain fiber, particularly soluble fiber, and risk of coronary heart

disease (Sec. 101.77); and fruits and vegetables and cancer

(Sec. 101.78) is a statement that development of the particular disease

depends on many factors.

It is well documented over the past 10 years that consumers are

generally aware that development of major chronic diseases, such as

cancer and coronary heart disease, is dependent on a number of

different factors such as smoking, excess body weight, family history

of the disease, exposure to environmental chemicals, and dietary and

other factors (Refs. 9 and 10). Additionally, the requirement that

authorized claims use the term ``may'' or ``might'' to relate the

ability of the substance that is the subject of the claim to reduce the

risk of the corresponding disease or health-related condition is an

indication to consumers of the multifactorial nature of the disease or

health-related condition. In responding to comments on the scientific

standard for health claims as to whether or not a claim based on

preliminary scientific data would be consistent with that standard, the

agency said:

* * * Further, absolute claims about diseases affected by diet

are generally not possible because such diseases are almost always

multifactorial. Diet is only one factor that influences whether a

person will get such a disease. For example, in the case of calcium

and osteoporosis, genetic predisposition (e.g., where there is a

family history of fragile bones with aging) can play a major role in

whether an individual will develop the disease. Because of factors

other than diet, some individuals may develop the disease regardless

of how they change their dietary patterns to avoid the disease. For

those individuals, a claim that changes in dietary patterns will

reduce the risk of disease would be false. Thus, health claims must

be free to use the term ``may'' with respect to the potential to

reduce the risk of disease. However, use of this term would not be

appropriate for health claims on food labeling where significant

scientific agreement does not exist that there is a high probability

that a reduction in disease risk will occur.

(58 FR 2478 at 2505.)

Given these facts, as part of its review of required elements for

all health claims the agency has reconsidered the need to remind

consumers of the multifactorial nature of hypertension, heart disease,

and cancer. Based on its review, FDA tentatively concludes that the

statement of that fact in each claim can be made optional. In place of

the requirement for stating the multifactorial nature of the disease,

the agency proposes to substitute a requirement that the claim not

imply that the substance that is the subject of the health claim is the

only recognized risk factor for the corresponding disease or health-

related condition. Thus, the agency tentatively concludes that the

concept of the multifactorial nature of the disease or health-related

condition for each health claim will be preserved without adding

additional words to the claim. The agency requests comment on whether

consumers will be misled to believe reduction of risk will be achieved

if the multifactorial nature of

[[Page 66220]]

the disease or health-related condition is not stated in the claim.

Accordingly, the agency is proposing to revise

Secs. 101.73(c)(2)(i)(F), 101.74(c)(2)(i)(E), 101.75(c)(2)(i)(E),

101.76(c)(2)(i)(D), 101.77(c)(2)(i)(F), and 101.78(c)(2)(i)(I) in

similar fashion to ensure that the health claim not imply that there is

only one recognized risk factor for the development of the

corresponding disease or health-related condition. The agency is also

proposing to revise Secs. 101.73(d)(1), 101.74(d)(1), 101.75(d)(1),

101.76(d)(2), 101.77(d)(1), and 101.78(d)(2) to state that development

of the disease in question depends on many factors and to list the

relevant factors for each disease. For consistency, the agency is also

proposing to revise the model claims to reflect the proposed revisions

to Secs. 101.73, 101.74, 101.75, 101.76, 101.77, and 101.78.

In addition, the agency is proposing to correct Sec. 101.77(e) by

adding the phrase ``and the risk of coronary heart disease'' which was

inadvertently omitted in the final rule.

The health claim for fruits and vegetables and cancer (Sec. 101.78)

contains one additional element that FDA tentatively concludes could be

optional instead of a mandatory part of the claim. In

Sec. 101.78(c)(2)(i)(D) the regulation states:

The claim characterizes the food bearing the claim as containing

one or more of the following, for which the food is a good source

under Sec. 101.54: dietary fiber, vitamin A, or vitamin C.

This required statement is very similar to the one required by

Sec. 101.78(c)(2)(i)(C):

The claim characterizes fruits and vegetables as foods that are

low in fat and may contain vitamin A, vitamin C, and dietary fiber.

The agency believes that the statement required by

Sec. 101.78(c)(2)(i)(C) is necessary to describe the relationship

between the food and the disease. In the 1993 health claims final rule,

FDA stated that by requiring that all characterizing nutrients be

identified as characteristic of dietary patterns rich in fruits and

vegetables without specifically attributing reduced cancer risk to a

single nutrient, the claim is consistent with current scientific

knowledge. However, the requirement in Sec. 101.78(c)(2)(i)(D)

identifies for the consumer which of the characterizing nutrients is

contributed by the labeled food. FDA tentatively concludes that this

information need not be a required element of the claim because it is

available as part of the nutrition label.

Therefore, the agency has tentatively concluded that the

information in Sec. 101.78(c)(2)(i)(D) can be made optional.

Accordingly, the agency is proposing to remove Sec. 101.78(c)(2)(i)(D);

redesignate Sec. 101.78(d)(3) through (d)(5) as Sec. 101.78(d)(4)

through (d)(6), and add new Sec. 101.78(d)(3) which reads:

The claim may characterize fruits and vegetables that meet the

requirements described in paragraph (c)(2)(ii) of this section as

foods that are low in fat and that contain (or are a good source of)

one or more of vitamin A, vitamin C, or dietary fiber.

FDA is also proposing to revise the model health claims in

Sec. 101.78(e) to reflect these changes.

3. Abbreviated Health Claims

In addition to eliminating some of the requirements for a full

health claim, as stated above, NFPA requested that FDA permit the use

of abbreviated health claims in labeling, such as on the principal

display panel. FDA has reviewed the health claims as it is proposing to

revise them to determine whether the required elements can be

reorganized in accordance with proposed Sec. 101.14(d)(2)(iv) to

facilitate their use on the food label.

With the revisions to Secs. 101.73, 101.74, 101.75, 101.76, 101.77,

and 101.78 proposed in this document, the agency tentatively finds that

all of the required elements for each of the claims are required under

section 403(a) of the act to ensure that the claims are truthful and

not misleading as well as under section 403(r) to ensure that they are

scientifically valid. Accordingly, the agency tentatively concludes

that there is no basis upon which it can propose to permit the

splitting of these required elements between the principal display

panel and another part of the food label.

Using the health claim for dietary fat and cancer as an example,

the agency is proposing to remove the requirement that the claim state

that cancer is a multifactorial disease. The remaining specific

requirements in Sec. 101.73(c)(2)(i)(A) through (c)(2)(i)(E) are

necessary so that claims on the relationship between dietary fat and

cancer are truthful, not misleading, and scientifically valid. A claim

consistent with these requirements can be expressed in 11 or fewer

words (e.g., ``A low fat diet may reduce the risk of some cancers'').

These requirements also ensure that consumers will be able to

understand the relative significance of the information presented in

the claim in the context of a total daily diet. Accordingly, the agency

tentatively finds that there is no need to divide the required elements

of Sec. 101.73 into those that must be included whenever the claim is

presented and those that need only be included as part of the full

claim. Based on the same reasoning, FDA has reached the same judgment

about the elements of the claims authorized by Secs. 101.74 through

101.78.

The agency tentatively concludes, however, that such a split is

appropriate among the required elements of health claims on calcium and

osteoporosis (Sec. 101.72). The various proposed revisions for the

specific requirements in Sec. 101.72(c)(2)(i) would produce a claim

that is shorter than is provided for in the current regulation.

Nonetheless, even with the proposed revisions, the length of the claim

that would be required under Sec. 101.72 is such that, to facilitate

use of the claim, FDA is proposing to distinguish between those

elements necessary to ensure that the claim is truthful and not

misleading, and those elements that are necessary to understand the

significance of the claim in the context of the total daily diet.

Section 101.72(c)(2)(i)(A), which the agency is proposing to

revise, sets forth the most important requirement. It establishes the

essence of the calcium/osteoporosis claim in that it requires clarity

in a statement that associates adequacy of dietary calcium intake over

a lifetime with a reduced risk of osteoporosis, a degenerative disease

that affects more than 25 million Americans, particularly

postmenopausal women and the elderly, and that is manifested by an

incidence of 1.5 million bone fractures annually (Ref. 6). This

provision sets out information that is fundamental if a claim

associating calcium and osteoporosis is to be truthful and not

misleading.

Section 101.72(c)(2)(i)(C), which requires that the claim not

attribute any particular degree of risk reduction to adequate calcium

intake is also necessary to ensure that claims are truthful, not

misleading, and scientifically valid. Compliance with this requirement,

however, does not add any words to the claim.

For the remaining requirements, Sec. 101.72(c)(2)(i)(B) prohibits

the implication that risk for the disease applies equally across the

U.S. population. Instead, it requires identification of that segment of

the population that is most at risk for developing the disease later in

life, women in their bone forming years. The agency requires this

information in response to section 403(r)(3)(b)(iii) of the act, which

as stated above, requires that the claim accurately represent the

relationship between calcium and osteoporosis in a manner that is

comprehensible to the public. It is also under section

403(r)(3)(b)(iii) of the act

[[Page 66221]]

that FDA is requiring in Sec. 101.72(c)(2)(i)(D) that the claim

disclose that further benefit does not derive from a daily dietary

intake of calcium that exceeds 2,000 mg.

Given these bases for the calcium/osteoporosis claim, an

abbreviated claim consistent with the principles proposed earlier in

this document may be developed that sets out the information required

under Sec. 101.72(c)(2)(i)(A) and (c)(2)(i)(C). To reflect this fact,

the agency is proposing to renumber current Sec. 101.72(c)(2)(ii),

which deals with the nature of a food bearing a calcium/osteoporosis

health claim, as Sec. 101.72(c)(2)(iii), and it is proposing a new

Sec. 101.72(c)(2)(ii) that describes how the health claim is to be

presented on the label or in labeling. This proposed new paragraph

states that all of the elements listed in Sec. 101.72(c)(2)(i) must be

included in one presentation of the claim on the label or labeling.

However, it also provides that a short, simple statement of the claim

that includes the elements in Sec. 101.72(c)(2)(i)(A) and (c)(2)(i)(C),

and thus that is truthful, not misleading, and scientifically valid,

may be used on the principal display panel as long as the full claim

appears on the label or in the labeling, and, there is a referral

statement to the full claim in immediate proximity to the abbreviated

statement.

The referral statement that FDA is proposing accompany the

abbreviated claim is consistent with that provided for in the general

requirements for nutrient content claims (Sec. 101.13) and health

claims (Sec. 101.14(d)(2)(iv)). Because this referral statement is

short, it is also consistent with the use of an abbreviated claim.

In the 1993 health claims final rule, the agency stated that it did

not believe that it is appropriate to use abbreviated health claims as

referral statements (58 FR 2478 at 2512). The agency was concerned that

an abbreviated claim did not include facts that are material in light

of the representation that is made and that are necessary to understand

the claim in the context of the daily diet. The agency was concerned

that such confusion is possible whenever the full health claim

information is in a location different from that of the reference

statement, and that such confusion is especially likely to occur when a

multiplicity of labeling is associated with a product. If these

concerns can be addressed, however, the use of an abbreviated claim on

the principal display panel would facilitate use of the claim and, as a

result, the communication of information that will assist consumers in

achieving healthful dietary practices.

The agency has tentatively concluded that this proposed rule

addresses these concerns. It is providing for an abbreviated statement

that reflects the facts that are material under section 201(n) of the

act (21 U.S.C. 321(n)) and that are necessary to ensure that the claim

is scientifically valid. It is also providing for an accompanying

referral statement to additional information that is necessary for a

full understanding of the claim. The agency is concerned, however,

about the possibility that consumers may not read the complete claim,

and thus that they will not have all the facts necessary to fully

understand the significance of the claim being made and to comprehend

the claim in the context of the daily diet. For this reason, the agency

is asking for data to demonstrate that permitting an abbreviated claim

in the manner that FDA has proposed will not significantly decrease the

likelihood that consumers will read the full claim.

In Sec. 101.72(c)(2)(ii)(A) and (c)(2)(ii)(B), the agency is

proposing requirements for the type size and location of the referral

statement that are consistent with those for nutrient content claims in

Sec. 101.13(g)(1) and (g)(2).

FDA has long held that accompanying information should be in a size

reasonably related to that of the information that it modifies. Section

403(f) of the act requires that information required under the act be

placed on the label with such conspicuousness as to render it likely to

be read. Section 403(r)(2)(B) of the act requires that a referral

statement for nutrient content claims appear prominently, although it

does not specify requirements such as to type size or style.

For nutrient content claims, FDA established type size requirements

for referral and disclosure statements that are related to the area of

the surface bearing the principal display panel rather than to the type

size used for the nutrient content claim. The proportionality between

size of the referral statement and the size of the label panel ensures

that the referral statement is presented with appropriate prominence.

However, when the claim is less than twice what the minimum size of the

referral statement would be, given the size of the label and

Sec. 101.105(i), the type size of the referral statement may be less

than that required under Sec. 101.105 for net quantity of contents. In

such circumstances, the referral statement is of appropriate prominence

if it is at least one-half the size of the claim and not less than one-

sixteenth of an inch. This approach to the type size requirement for

the referral statement provides additional flexibility to firms in

utilizing label space but still ensures adequate prominence for this

statement.

Because, under this proposal, health claim referral statements are

to be used in a manner that is similar to how nutrient content claim

referral statements are used, and because they are likely to appear on

the principal display panel, the agency tentatively concludes that a

health claim referral statement should be subject to the same type size

requirements as those for nutrient content claims. Therefore, the

agency tentatively concludes that the requirements for the referral

statement set forth in Sec. 101.72(c)(2)(ii)(A) and (c)(2)(ii)(B) are

appropriate when an abbreviated health claim is used, and it is

including them in this proposed rule.

In concert with the proposed requirements for an abbreviated health

claim, the agency is including an abbreviated health claim among the

examples of other model claims in proposed Sec. 101.72(e).

E. Disclosure Versus Disqualifying Nutrient Levels for Health Claims

Section 403(r)(3)(A)(ii) of the act provides that a health claim

may only be made for a food that ``does not contain, as determined * *

* by regulation, any nutrient in an amount which increases to persons

in the general population the risk of a disease or health-related

condition which is diet related, taking into account the significance

of the food in the total daily diet.'' This section helps to ensure

that consumers who rely on health claims will be consuming foods that

will assist them in structuring a healthful diet that meets dietary

guidelines.

As discussed more fully in the preamble to the 1993 health claims

final rule, the agency implemented this provision by considering a

food's role in the total daily diet and calculating levels of total

fat, saturated fat, cholesterol, and sodium that would increase the

risk of disease or health-related conditions in the general population.

FDA calculated these levels by considering the number of foods consumed

each day, as well as the number of foods that are likely to contain

significant levels of these nutrients.

The agency has established different disqualifying levels for

different types of foods, depending on the role that they play in the

daily diet. Section 101.14(a)(5) defines the disqualifying level for

individual foods as 20 percent of the DV's for total fat, saturated

fat, cholesterol, and sodium. These levels

[[Page 66222]]

translate to 13.0 grams (g) of total fat, 4.0 g of saturated fat, 60 mg

of cholesterol, and 480 mg of sodium per reference amount customarily

consumed, per label serving size, and for foods with reference amounts

customarily consumed of 30 g or less or 2 tablespoons or less, per 50

g. The regulations make additional allowances for main dish products

and meal-type products. The disqualifying levels for main dish and meal

products are 30 percent and 40 percent of the DV, respectively. These

different levels are consistent with the legislative history, which

states, ``a particular level of fat in a frozen dinner might not

trigger the provision, whereas the same amount of fat in a snack food

might trigger it.''

A food that exceeds the disqualifying level for any of the four

disqualifying nutrients may not bear a health claim unless the agency

has granted an exemption ``based on a finding that such a claim would

assist consumers in maintaining healthy dietary practices.'' (Section

403(r)(3)(A)(ii) of the act.) To date, the agency has received no

petitions for an exemption from this provision.

The NFPA petition requested that the defined disqualification

levels be converted to disclosure levels under certain circumstances.

More specifically, the petition suggested that ``the presence of one of

these nutrients at the prescribed level would require disqualification

only if the nutrient was found in another health claim regulation to be

directly and adversely related to the disease mentioned in the claim.''

The petition went on to state that ``[i]f the nutrient is not so

directly related to the disease to which the claim refers, the

regulations would require only disclosure by an appropriate referral

statement in conjunction with the health claim on the label, as the

regulations now require for nutrient content claims.''

As stated in the May 11, 1995, letter to NFPA, FDA concludes that a

generic change in its regulations would not be consistent with the

underlying goals of the NLEA. The current disqualifying levels assist

consumers in constructing total daily diets that meet dietary

guidelines. The agency considered the role a food plays in the daily

diet when it calculated the disqualifying levels. Health claims on

foods with levels of fat, saturated fat, cholesterol, or sodium that

exceed the disqualifying levels would encourage increased intake of

these foods and would make it difficult for consumers to follow the

Surgeon General's recommendations and to construct a healthful diet.

Even with the current disqualification levels, consumers could reach

the DV's for total fat, saturated fat, cholesterol, or sodium by eating

as few as five foods that bear health claims.

The agency considers the current disqualification rules to be

consistent with congressional intent. Congress contemplated that health

claims would be reserved for those foods that can contribute to a

healthful diet. As the House Report states, ``Health claims supported

by a significant scientific agreement can reinforce the Surgeon

General's recommendations and help Americans to maintain a balanced and

healthful diet.'' (See H. Rept. 101-538, 101st Cong., 2d sess. pp. 9-10

(1990).)

Nevertheless, the agency tentatively finds that there may be some

instances where disclosure rather than disqualification is appropriate.

While FDA continues to believe that exceptions should be granted on a

case-by-case basis, using a petition process, the agency recognizes

that further guidance on the criteria that it will use to evaluate

petitions for exceptions would be useful. FDA is, therefore, proposing

to amend its regulations to give such guidance.

Proposed Sec. 101.70(f) provides guidance for petitioners

requesting an exception to the prohibition in Sec. 101.14(e)(3) against

health claims for foods exceeding the disqualifying levels identified

in Sec. 101.14(a)(5). This proposed amendment to the petition

procedures sets out some of the factors that the agency will consider

when evaluating a petition.

The first factor that FDA is proposing to list is whether the risk

of the disease or health-related condition is of such public health

significance, and the role of the diet so critical, that

disqualification is not appropriate (proposed Sec. 101.70(f)(1)). The

agency recognizes that there may be instances where extraordinary

efforts are needed to address a particular public health problem. In

such cases, the agency would consider providing for disclosure rather

than disqualification levels.

The second factor is whether the availability of foods that qualify

for a health claim is adequate to address the public health concern

that is the subject of the health claim (proposed Sec. 101.70(f)(2)).

The agency intends to consider whether the application of the claim is

so limited because of the disqualification levels that it will not be

possible to meet the public health goal of the health claim. If only a

limited number of food products qualify to bear the claim because of

the disqualifying levels, the agency would consider providing for

disclosure rather than disqualification levels.

The third factor that FDA intends to consider is whether there is

some evidence that the population to which the health claim is targeted

is not at risk for the disease or health-related condition associated

with the disqualifying nutrient (proposed Sec. 101.70(f)(3)). Although

the current disqualifying nutrients are associated with diseases or

health-related conditions that pose risks to the general population,

there may be some categories of foods that are targeted to specific

subpopulations that are not at particular risk for the disease or

health-related condition associated with the disqualifying nutrient

(toddlers, for example). The agency would be willing to look at data

and to consider whether an exception to the disqualifying levels should

be made for foods intended for such subgroups.

Related to this criterion, is the question of whether there is

evidence that consumers can identify themselves as being at risk for a

particular disease or health-related condition associated with the

disqualifying levels. For instance, some individuals can already

identify themselves as being sensitive to sodium and, therefore, would

recognize the risk of a high sodium food if it were disclosed. If the

ability to self-identify for these risks becomes widespread, disclosure

might be sufficient to reduce the risk from the disqualifying nutrient.

FDA would expect to receive data that demonstrate that this ability

exists, however, before it would be willing to grant an exemption on

this basis.

Finally, the agency intends to consider whether there are any other

public health reasons for providing for disclosure rather than

disqualification (proposed Sec. 101.70(f)(4)). The agency does not

consider the above list of criteria exhaustive. There may be other

criteria that would be useful in determining whether the agency should

provide for disclosure rather that disqualification levels for health

claims, and the agency is open to considering such factors.

The agency requests comments on the appropriateness of these

criteria.

The agency notes that there are ways to convey important health

information other than through health claims. A food may still be able

to bear a nutrient content claim or a structure/function claim in order

to highlight a particular attribute even if it exceeds the

disqualification level for a health claim. For example, while whole

milk may not be able to bear a calcium and osteoporosis health claim,

it can still bear a ``high calcium'' nutrient content claim, so long as

the levels of fat and saturated fat are disclosed. Similarly,

[[Page 66223]]

cooking oils that are lower in saturated fat may not be able to bear a

``healthy heart'' claim but can still bear a ``low'' or ``less''

saturated fat nutrient content claim.

In addition, some products can make other truthful and not

misleading claims. For example, the label of whole milk can state

``Calcium builds strong bones.'' While such a claim is not considered a

health claim under the 1990 amendments, it still conveys important

dietary advice useful to consumers in constructing a healthful diet.

V. Environmental Impact

The agency has determined under 21 CFR 25.24(a)(11) that this

action is of a type that does not individually or cumulatively have a

significant effect on the human environment. Therefore, neither an

environmental assessment nor an environmental impact statement is

required.

VI. Analysis of Impacts

FDA has examined the impacts of the proposed rule under Executive

Order 12866 and the Regulatory Flexibility Act (Pub. L. 96-354).

Executive Order 12866 directs agencies to assess all costs and benefits

of available regulatory alternatives and, when regulation is necessary,

to select regulatory approaches that maximize net benefits (including

potential economic, environmental, public health and safety, and other

advantages; distributive impacts; and equity). The agency believes that

this proposed rule is consistent with the regulatory philosophy and

principles identified in the Executive Order. In addition, the proposed

rule is not a significant regulatory action as defined by the Executive

Order and so is not subject to review under the Executive Order.

FDA is proposing to: (1) Specify circumstances under which synonyms

may be used, authorizing the use of unlisted synonyms provided that

they are properly anchored to a listed term; (2) exempt certain types

of products from the 10 percent nutrient contribution requirement; (3)

provide the basis for shorter health claims by eliminating some of the

required elements; and (4) permit an abbreviated health claim to be

used on the principal display panel. FDA is also providing guidance for

petitioners requesting an exception to the prohibition against health

claims for foods exceeding FDA's defined disqualifying levels. The

agency anticipates that the costs of this proposed rule will be

minimal. If this rule is finalized as proposed, it will not require any

manufacturers currently making claims to change their labels or

labeling. Also, this rule may reduce the costs of making future claims

by reducing the uncertainty and relaxing the requirements of the

petition process for claims.

Although many health claims have appeared on a variety of products,

the agency is concerned that health claims are not being used as

extensively as they could be. To the extent that valid claims are not

being used, a cost is imposed on society in that some valuable

information may not be conveyed to consumers. This proposed rule will

reduce the cost of lost beneficial information by making it easier for

firms to make nutrient content and health claims. The agency is aware

that the food label or labeling is a major means of providing

information on foods at the point-of-purchase. By adopting a less

restrictive approach to claims, the agency is providing industry with a

method by which the label can be used to inform consumers of the health

benefits of foods in such a way that will catch the attention of

consumers. As long as the claims are truthful, not misleading, and

scientifically valid, the additional information will benefit consumers

by reinforcing the Surgeon General's recommendations and helping

consumers maintain healthful dietary practices. In addition, the

greater flexibility provided to industry will increase the incentive to

develop more healthful products.

The Regulatory Flexibility Act requires analyzing options for

regulatory relief for small businesses. The current claims regulations

may have discouraged small businesses from making valid nutrient

content claims and health claims. To the extent that this rule relaxes

the restrictions on the ability of firms to use claims on the labels or

in the labeling of their products, this rule will benefit small firms.

In accordance with the Regulatory Flexibility Act, the agency certifies

that the proposed rule will not have a significant economic impact on a

substantial number of small businesses.

VII. Paperwork Reduction Act

FDA tentatively concludes that this proposed rule contains no

reporting, recordkeeping, labeling, or other third party disclosure

requirements; thus there is not ``information collection''

necessitating clearance by the Office of Management and Budget.

However, to ensure the accuracy of this tentative conclusion, FDA is

seeking comment on whether this proposed rule to permit additional

flexibility in the use of health claims and synonyms for nutrient

content claims on food labels imposes any paperwork burden.

VIII. Comments

Interested persons may, on or before March 20, 1996, submit to the

Dockets Management Branch (address above) written comments regarding

this proposal. Two copies of any comments are to be submitted, except

that individuals may submit one copy. Comments are to be identified

with the docket number found in brackets in the heading of this

document. Received comments may be seen in the office above between 9

a.m. and 4 p.m., Monday through Friday.

IX. References

The following references have been placed on display in the Dockets

Management Branch (address above) and may be seen by interested persons

between 9 a.m. and 4 p.m., Monday through Friday.

1. House Committee on Energy and Commerce, ``Nutrition Labeling

and Education Act of 1990,'' 101st Congress, 2d sess., Report 101-

538, pp. 9-10, June 13, 1990.

2. Committee on the Nutrition Components of Food Labeling, Food

and Nutrition Board, IOM, National Academy of Science, ``Nutrition

Labeling, Issues and Directions for the 1990's,'' Washington, DC,

National Academy Press, 1990.

3. United States Department of Agriculture, Human Nutrition

Information Services, ``USDA's Food Guide Pyramid,'' Home and Garden

Bulletin No. 249, April, 1992.

4. ``The Surgeon General's Report on Nutrition and Health,''

DHHS, Public Health Service Publication No. 88-50210 (Government

Printing Office Stock No. 017-001-00465-1), U.S. Government Printing

Office, Washington, DC, 1988.

5. Committee on Diet and Health, Food and Nutrition Board,

Commission on Life Sciences, National Research Council, National

Academy of Science, ``Diet and Health: Implications for Reducing

Chronic Disease Risk,'' National Academy Press, Washington, DC,

1989.

6. National Institutes of Health, Office of the Director, ``NIH

Consensus Statement, Optimal Calcium Intake,'' vol. 12, No. 4, June

6-8, 1994. Available from: NIH Consensus Program Information

Service, P.O. Box 2577, Kensington, MD 20891, 1-800-644-6627.

7. Levy, A., Food and Drug Administration, Center for Food

Safety and Applied Nutrition, Division of Market Studies, ``Summary

Report on Health Claims Focus Groups,'' June 15, 1995.

8. Dietary Supplement Health and Education Act of 1994 (Pub. L.

103-417), October 25, 1994.

9. Technical Report--Cancer Prevention Awareness Survey--Wave

II, Office of Cancer Communications, National Cancer Institute,

National Institutes of Health, Bethesda, MD, November 1986.

10. Brenda Derby, Memorandum to Victor Frattali, ``Consumer

Understanding of

[[Page 66224]]

Multifactoriality of Disease,'' October 25, 1995.-

List of Subjects in 21 CFR Part 101

Food labeling, Nutrition, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act, and

under authority delegated to the Commissioner of Food and Drugs, it is

proposed that 21 CFR part 101 be amended as follows:

PART 101--FOOD LABELING

1. The authority citation for 21 CFR part 101 continues to read as

follows:

Authority: Secs. 4, 5, 6 of the Fair Packaging and Labeling Act

(15 U.S.C. 1453, 1454, 1455); secs. 201, 301, 402, 403, 409, 701 of

the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 342,

343, 348, 371).

2. Section 101.13 is amended by revising the introductory text of

paragraph (b) and adding new paragraph (r) to read as follows:

Sec. 101.13 Nutrient content claims--general principles.

* * * * *

(b) A claim that expressly or implicitly characterizes the level of

a nutrient (nutrient content claim) of the type required in nutrition

labeling under Sec. 101.9 with the exception of such claims on

restaurant menus and except as noted in paragraph (r) of this section

for unlisted synonyms, may not be made on the label or in labeling of

foods unless the claim is made in accordance with this regulation and

with the applicable regulations in subpart D of this part or in part

105 or part 107 of this chapter.

* * * * *

(r) Expressed synonyms for nutrient content claims may be used,

provided:

(1) The term is listed as a synonym of a defined term in the

regulations in subpart D of this part or in part 105 or part 107 of

this chapter; or

(2) The term is used in a manner that complies with the following

requirements:

(i) Such term is not misleading and, in the context of the entire

label, is reasonably understood by consumers to be a synonym of a term

listed in subpart D of this part or in part 105 or part 107 of this

chapter;

(ii)(A) The term that is listed in subpart D of this part or in

part 105 or part 107 of this chapter, and for which the unlisted term

is being used as a synonym, appears prominently and conspicuously on

the label, such that it is:

(1) Immediately adjacent (with no intervening material) to the most

prominent use of the unlisted synonym (as determined in accordance with

Sec. 101.13(j)(2)(iii)); and

(2) At least half as prominent (including type size, style, and

color) as the unlisted synonym authorized under this paragraph.

(B) If the term listed in subpart D of this part or in part 105 or

part 107 of this chapter is more than twice as prominent on a label as

the synonym authorized under this paragraph such that the claimed

nutrient level is clearly understood (e.g., a claim in the statement of

identity versus an unlisted synonym used only in a paragraph in small

sized type), the term listed in subpart D of this part or in part 105

or part 107 of this chapter need not be placed adjacent to the unlisted

synonym authorized under this paragraph.

(iii) The unlisted synonym is used in conformance with all the

requirements for the use of the defined term, i.e., the referral

statement required in Sec. 101.13(g) and any other required label

statements appear in the prescribed manner; and

(iv) This paragraph does not authorize a term listed in subpart D

of this part or in part 105 or part 107 of this chapter to be used in

conjunction with an unlisted qualifying term (e.g., ``extra low,''

``extra high,'' ``especially good source,'' or ``great source'').

3. Section 101.14 is amended by revising paragraphs (d)(2)(iv) and

(e)(6) to read as follows:

Sec. 101.14 Health claims: general requirements.

* * * * *

(d) * * *

(2) * * *

(iv) All information required to be included in the claim appears

in one place without other intervening material, except that the

principal display panel of the label or labeling may bear:

(A) The reference statement, ``See---------- for information about

the relationship between-------- and ---------- ,'' with the blanks

filled in with the location of the labeling containing the health

claim, the name of the substance, and the name of the disease or

health-related condition (e.g., ``See attached pamphlet for information

about calcium and osteoporosis''), with the entire claim appearing

elsewhere on the other labeling, Provided that, where any graphic

material (e.g., a heart symbol) constituting an explicit or implied

health claim appears on the label or labeling, the reference statement

or the complete claim shall appear in immediate proximity to such

graphic material; or

(B) As authorized under subpart E of this part, an abbreviated

claim consisting only of a truthful, nonmisleading, and scientifically

valid description of the relationship between the substance and the

disease or health-related condition, Provided that:

(1) Such an abbreviated claim is accompanied by a reference

statement to the complete health claim;

(2) The reference statement is prominent and in immediate proximity

to the abbreviated claim; and

(3) The complete health claim appears on the same label, or in the

same labeling, in which the abbreviated claim appears.

* * * * *

(e) * * *

(6) Except for dietary supplements, fruit or vegetable products

composed solely of fruits and vegetables, enriched grain products that

conform to a standard of identity in part 136, 137, or 139 of this

chapter, and bread which conforms to the standard of identity for

enriched bread in Sec. 136.115 of this chapter except that it contains

whole wheat or other grain products not permitted under that standard,

or where provided for in other regulations in part 101, subpart E, the

food contains 10 percent or more of the Reference Daily Intake or Daily

Reference Value for vitamin A, vitamin C, iron, calcium, protein, or

fiber per reference amount customarily consumed prior to any nutrient

addition.

* * * * *

4. Section 101.70 is amended in paragraph (f) by adding in the

model petition new text immediately preceding the last undesignated

paragraph of section B to read as follows:

Sec. 101.70 Petitions for health claims.

* * * * *

(f) * * *

B. * * *

In deciding the merits of a petition filed for an exception to the

prohibition in Sec. 101.14(e)(3) against health claims for foods

exceeding the disqualifying levels identified in Sec. 101.14(a)(5), the

agency will consider the following factors:

1. The public health significance of the risk of the disease or

health-related condition that is the subject of the claim and the role

that the diet plays in decreasing that risk;

2. The availability of foods that qualify for a claim to address

the underlying public health concerns;

3. Evidence demonstrating the population to which the health claim

is targeted is not at risk for the disease or health-related condition

associated with the disqualifying nutrient, including,

[[Page 66225]]

but not limited to, the ability of individuals to identify themselves

as being at risk for the disease or health-related condition associated

with the disqualifying nutrient; and

4. All other evidence demonstrating the public health need for

waiving the disqualification requirements.

* * * * *

5. Section 101.72 is amended by revising paragraph (c)(2)(i); by

redesignating paragraphs (c)(2)(ii) and (d)(2) as (c)(2)(iii) and

(d)(5), respectively; by adding new paragraphs (c)(2)(ii), (d)(2),

(d)(3), and (d)(4); and by revising paragraph (e) to read as follows:

Sec. 101.72 Health claims: calcium and osteoporosis.

* * * * *

(c)(2) Specific requirements. (i) Nature of the claim. A health

claim associating calcium with a reduced risk of osteoporosis may be

made on the label or labeling of a food described in paragraph

(c)(2)(iii) of this section, provided that:

(A) The claim makes clear that adequate calcium intake as part of a

healthful diet throughout life is essential to reduce the risk of

osteoporosis. The claim does not imply that adequate dietary calcium

intake is the only recognized risk factor for the development of

osteoporosis;

(B) The claim does not state or imply that the risk of osteoporosis

is equally applicable to the general United States population. The

claim shall identify the population at particular risk for the

development of osteoporosis as women in their bone forming years from

approximately 11 to 35 years of age. An optional statement that further

characterizes this and other populations at risk for developing

osteoporosis may be made in accordance with paragraph (d)(3) of this

section;

(C) The claim does not attribute any degree to which maintaining

adequate calcium intake throughout life may reduce the risk of

osteoporosis; and

(D) The claim states that total dietary intake of calcium greater

than 2,000 milligrams (mg) per day (200 percent of the DV for calcium

for adults and children 4 or more years of age or 154 percent of the

daily value (DV) for pregnant or lactating women) provides no further

benefit to bone health in reducing the risk of osteoporosis. This

requirement does not apply to a food that provides 1,500 mg or less of

calcium per day (150 percent or less of the DV for calcium for adults

and children 4 or more years of age or 115 percent or less of the DV

for pregnant or lactating women) when used as directed in labeling.

(ii) Presentation of the claim. All of the elements listed in

paragraph (c)(2)(i) of this section must be included in one

presentation of the claim displayed prominently on the label or

labeling on which the claim appears. Other presentations of the claim

on that label or labeling, including on the principal display panel,

need not include the information in paragraphs (c)(2)(i)(B) and

(c)(2)(i)(D) of this section provided that, displayed prominently and

in immediate proximity to such claim, the following referral statement

is used: ``See -------- for more information'' with the blank filled in

with the identity of the panel on which is presented the statement of

the claim that includes all of the elements in paragraph (c)(2)(i) of

this section.

(A)-The referral statement ``See [appropriate panel] for more

information'' shall be in easily legible boldface print or type, in

distinct contrast to other printed or graphic matter, that is no less

than that required by Sec. 101.105(i) for net quantity of contents,

except where the size of the claim is less than two times the required

size of the net quantity of contents statement, in which case the

referral statement shall be no less than one-half the size of the claim

but no smaller than one-sixteenth of an inch.

(B) The referral statement shall be immediately adjacent to any

presentation of the health claim that does not include all of the

elements of paragraph (c)(2)(i) of this section, and there may be no

intervening material between the claim and the referral statement. If

the abbreviated health claim appears on more than one panel of the

label, the referral statement shall be adjacent to the claim on each

panel except for the panel that bears the full health claim where it

may be omitted.

-* * * * *

(d) * * *

(2) The claim may list specific risk factors for osteoporosis,

identifying them among the multifactorial risks for the disease. Such

factors include a person's sex, age, and race. The claim may state that

an adequate amount of exercise is also needed to reduce risk for the

disease.

(3) The claim may further identify the population at particular

risk for the development of osteoporosis as including white (or

``Caucasian'') women and Asian women in their bone forming years

(approximately 11 to 35 years of age). The claim may also identify

menopausal (or the term ``middle-aged'') women, persons with a family

history of the disease, and elderly (or ``older'') men and women as

being at risk.

(4) The claim may state that adequate calcium intake throughout

life is linked to reduced risk of osteoporosis through the mechanism of

optimizing peak bone mass during adolescence and early adulthood. The

phrase ``build and maintain good bone health'' may be used to convey

the concept of optimizing peak bone mass. When reference is made to

persons with a family history of the disease, menopausal women, and

elderly men and women, the claim may also state that adequate calcium

intake is linked to reduced risk of osteoporosis through the mechanism

of slowing the rate of bone loss.

-* * * * *

(e) Model health claims. The following are examples of model health

claims that may be used in food labeling to describe the relationship

between calcium and osteoporosis:

(1) Examples 1 and 2. Model health claims for a food that does not

require the statement specified in paragraph (c)(2)(i)(D) of this

section:

Especially for teen and young adult women, adequate calcium in a

healthful diet may reduce the risk of osteoporosis later in life.

A healthful diet with adequate calcium and regular exercise help

teen and young adult white and Asian women maintain good bone health

and may reduce their high risk of osteoporosis later in life.

(2) Example 3. Model health claims for a food labeled for use by

adults and children 4 or more years of age that requires the statement

specified in paragraph (c)(2)(i)(D) of this section:

Exercise and a healthful diet with enough calcium may help teen

and young adult women reduce their high risk of osteoporosis later

in life. Adequate calcium is important for everyone (women and men

at all ages) but daily intakes above 2,000 mg (200 percent of the

DV) may not provide added benefit.

(3) Example 4. Abbreviated model health claim for use with a full

health claim and that conforms with the requirements of paragraph

(c)(2)(ii) of this section:

Adequate calcium in a healthful diet may reduce the risk of

osteoporosis. See [appropriate panel] for more information.

6. Section 101.73 is amended by revising paragraphs (c)(2)(i)(F),

(d)(1), and (e)(1) to read as follows:

Sec. 101.73 Health claims: dietary lipids and cancer.

* * * * *

(c) * * *

(2) * * *

(i) * * *

(F) The claim does not imply that dietary fat consumption is the

only

[[Page 66226]]

recognized risk factor for the development of cancer.

* * * * *

(d) Optional information. (1) The claim may indicate that

development of cancer depends on many factors and identify one or more

of the following as risk factors for the disease: Family history of a

specific type of cancer, cigarette smoking, alcohol consumption,

overweight and obesity, ultraviolet or ionizing radiation, exposure to

cancer-causing chemicals, and dietary factors.

* * * * *

(e) * * *

(1) A low fat diet may reduce the risk of some cancers.

-* * * * *

7. Section 101.74 is amended by revising paragraphs (c)(2)(i)(E),

(d)(1), (e)(1), and (e)(2) to read as follows:

Sec. 101.74 Health claims: sodium and hypertension.

-* * * * *

(c) * * *

(2) * * *

(i) * * *

(E) The claim does not imply that dietary sodium consumption is the

only recognized risk factor for the development of high blood pressure.

-* * * * *

(d) Optional information. (1) The claim may indicate that

development of high blood pressure depends on many factors and identify

one or more of the following as risk factors for the disease in

addition to dietary sodium consumption: Family history of high blood

pressure, growing older, alcohol consumption, and excess weight.

-* * * * *

(e) * * *

(1) A low sodium diet may reduce the risk of high blood pressure.

(2) [This product] can be part of a low sodium, low salt diet that

might reduce the risk of hypertension or high blood pressure.

8. Section 101.75 is amended by revising paragraphs (c)(2)(i)(E),

(d)(1), (e)(1), and (e)(2) to read as follows:

Sec. 101.75 Health claims: dietary saturated fat and cholesterol and

risk of coronary heart disease.

-* * * * *

(c) * * *

(2) * * *

(i) * * *

(E) The claim does not imply that consumption of dietary saturated

fat and cholesterol is the only recognized risk factor for the

development of coronary heart disease.

-* * * * *

(d) Optional information. (1) The claim may indicate that coronary

heart disease risk depends on many factors and identify one or more of

the following in addition to saturated fat and cholesterol about which

there is general scientific agreement that they are major risk factors

for this disease: A family history of coronary heart disease, elevated

blood total and LDL-cholesterol, excess body weight, high blood

pressure, cigarette smoking, diabetes, and physical inactivity.

-* * * * *

(e) * * *

(1) Diets low in saturated fat and cholesterol may reduce the risk

of heart disease;

(2) Your risk of heart disease might be reduced by a diet low in

saturated fat and cholesterol and a healthy lifestyle;

-* * * * *

9. Section 101.76 is amended by revising paragraphs (c)(2)(i)(D),

(d)(2), (e)(1), and (e)(2) to read as follows:

Sec. 101.76 Health claims: fiber-containing grain products, fruits,

and vegetables and cancer.

-* * * * *

(c) * * *

(2) * * *

(i) * * *

(D) The claim does not imply that consumption of diets low in fat

and high in fiber-containing grain products, fruits, and vegetables is

the only recognized risk factor for a reduced risk of developing

cancer.

-* * * * *

(d) * * *

(2) The claim may indicate that development of cancer depends on

many factors and identify one or more of the following as risk factors

for the disease: Family history of a specific type of cancer, cigarette

smoking, alcohol consumption, overweight and obesity, ultraviolet or

ionizing radiation, exposure to cancer-causing chemicals, and dietary

factors.

-* * * * *

(e) * * *

(1) Low fat diets rich in fiber-containing grain products, fruits,

and vegetables may reduce the risk of some types of cancer.

(2) A diet low in fat and high in grain products, fruits, and

vegetables that contain fiber may reduce your risk of some cancers.

-* * * * *

10. Section 101.77 is amended by revising paragraphs (c)(2)(i)(F),

(d)(1), and (e) to read as follows:

Sec. 101.77 Health claims: fruits, vegetables, and grain products -

that contain fiber, particularly soluble fiber, and risk of -coronary

heart disease.

(c) * * *

(2) * * *

(i) * * *

(F) The claim does not imply that consumption of diets low in

saturated fat and cholesterol and high in fruits, vegetables, and grain

products that contain fiber, particularly soluble fiber, is the only

recognized risk factor for a reduced risk of developing coronary heart

disease.

-* * * * *

(d) Optional information. (1) The claim may indicate that

development of coronary heart disease depends on many factors and

identify one or more of the following as risk factors for the disease:

A family history of coronary heart disease, elevated blood-, total- and

LDL-cholesterol, excess body weight, high blood pressure, cigarette

smoking, diabetes, and physical inactivity.

-* * * * *

(e) Model health claims. The following model health claims may be

used in food labeling to characterize the relationship between diets

low in saturated fat and cholesterol and high in fruits, vegetables,

and grain products that contain soluble fiber and the risk of coronary

heart disease:

(1) Diets low in saturated fat and cholesterol and rich in fiber-

containing fruits, vegetables, and grain products may reduce the risk

of heart disease.

(2) A diet low in saturated fat and cholesterol and high in fruits,

vegetables, and grain products that contain fiber may lower blood

cholesterol levels and reduce your risk of heart disease.

11. Section 101.78 is amended by removing paragraph (c)(2)(i)(D);

by redesignating paragraphs (c)(2)(i)(E) through (c)(2)(i)(J) and

(d)(3) through (d)(5) as (c)(2)(i)(D) through (c)(2)(i)(I) and (d)(4)

through (d)(6), respectively; by revising newly redesignated paragraph

(c)(2)(i)(I), paragraphs (d)(2), (e)(1), and (e)(2); and by adding new

paragraph (d)(3) to read as follows:

Sec. 101.78 Health claims: fruits and vegetables and cancer.

-* * * * *

(c) * * *

(2) * * *

(i) * * *

(I) The claim does not imply that consumption of diets low in fat

and high in fruits and vegetables is the only recognized risk factor

for a reduced risk of developing cancer.

-* * * * *

[[Page 66227]]

(d) * * *

(2) The claim may indicate that development of cancer depends on

many factors and identify one or more of the following as risk factors

for the disease: Family history of a specific type of cancer, cigarette

smoking, alcohol consumption, overweight and obesity, ultraviolet or

ionizing radiation, exposure to cancer-causing chemicals, and dietary

factors.

(3) The claim may characterize fruits and vegetables that meet the

requirements described in paragraph (c)(2)(ii) of this section as foods

that are low in fat and that contain (or are a good source of) one or

more of vitamin A, vitamin C, or dietary fiber.

-* * * * *

(e) * * *

(1) Low fat diets rich in fruits and vegetables (foods that are low

in fat and may contain dietary fiber, vitamin A and vitamin C), may

reduce the risk of some types of cancer.

(2) A diet low in fat and high in certain fruits and vegetables,

foods that are low in fat and that may contain vitamin A and vitamin C,

may reduce your risk of some cancer.

Dated: December 13, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-31008 Filed 12-20-95; 8:45 am]

BILLING CODE 4160-01-F

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.